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ABSTRACT 
 
 Adipose tissue secretes over 100 different proteins and cytokines called adipokines. 
Adiponectin is one of the most intriguing adipokines because it is closely associated with insulin 
sensitivity and is an early marker for Type-2 diabetes mellitus in human beings. Cats are at risk 
for developing Type-2 diabetes with obesity, so it is important for researchers to understand the 
role adipokines, like adiponectin, play in feline metabolism. This project sought to lay the 
foundation for future research regarding feline adiponectin by sequencing adiponectin cDNA, 
measuring adiponectin’s expression in various tissues, validating and developing new techniques 
for measuring adiponectin in circulation, determining the influence of gender on adiponectin 
concentrations, and by monitoring changes in adiponectin as cats gain and lose fat mass. The 
results of this project revealed that adiponectin has a similar cDNA and amino acid sequence to 
other species and is secreted almost exclusively from adipose tissue. However, cats differed from 
other species in that visceral adipose tissue had more adiponectin expression than subcutaneous 
adipose tissue. Serum feline adiponectin was measured using a commercially available murine 
adiponectin ELISA, and the high molecular weight (HMW) form was detected using gel 
chromatography combined with ELISA. Neutered male cats may have lower concentrations of 
total adiponectin than female cats and lower percentages of HMW adiponectin than all other 
gender groups. Similar to humans, HMW adiponectin was more closely associated with 
improved glucose metabolism than total adiponectin. HMW adiponectin also correlated more 
closely with body fat mass than total adiponectin. Despite some unique characteristics, feline 
adiponectin appears similar in structure and function to adiponectin in other species.  
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CHAPTER I 
INTRODUCTION 
 
Project Summary 
The role of adipose tissue as a metabolically active organ is a rapidly expanding area of 
research. Discovery of cell-signaling proteins secreted by adipocytes, termed adipokines, 
dispelled the belief that fat is a passive tissue functioning solely for energy storage and 
insulation. To date, over one hundred adipokines have been identified and include adiponectin 
[1]. Circulating levels of serum adiponectin decrease as body fat mass rises. Studies in human 
beings and rodents demonstrate adiponectin is closely associated with insulin sensitivity and has 
beneficial affects on the cardiovascular system. Adiponectin’s role in metabolism and diabetes is 
of interest in feline medicine because cats are susceptible to developing Type-2 diabetes with 
obesity. Little research regarding feline adiponectin has been conducted. The goal of this project 
is to characterize feline adiponectin by sequencing its gene, measuring tissue expression of the 
hormone, determining gender’s influence on circulating levels, and tracking its relationship to 
insulin sensitivity during changes in adiposity associated with weight gain and weight loss. 
To provide a thorough understanding of adiponectin and its potential role in feline 
metabolism, this dissertation will begin with a discussion of normal adipocyte physiology and 
glucose metabolism. The pathogenesis of insulin resistance and its relationship to feline 
metabolism will then be addressed. The introductory material will conclude with a discussion of 
the various testing methods available for estimating insulin sensitivity and beta cell function. 
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Adipose Physiology 
Adipose Development  
 
Adipose tissue contains a variety of cell types. Adipocytes are the main parenchymal 
cells and make up 30-50% of adipose tissue [2, 3]. Other cells found in adipose include vascular 
and neural support cells, fibroblasts, red and white blood cells, and preadipocytes [2]. Adipose 
tissue expands with energy excess by hypertrophy (increase in cell size) and hyperplasia 
(increase in cell number). Adipocyte hyperplasia involves development and maturation of 
adipocyte precursor cells called preadipocytes. This process of adipogenesis is complex and 
much is still unknown. Most of the information available comes from in vitro studies of 
adipocyte precursor cell lines. Based on our current understanding, adipogenesis can be placed 
into two broad phases: determination and terminal differentiation [4]. Determination describes 
the process by which multipotent mesodermal stem cells develop into adipocyte precursors 
called preadipocytes. These  stems cells can also develop into muscle, bone, or cartilage, and a 
variety of factors and signals control their fate [4, 5]. Little is known about the determination 
phase of adipocyte development; however, the transcription regulators CCAAT-enhancer-
binding protein α (C/EBPα) and proliferation-activated receptor γ (PPARγ) are highly expressed 
in mature adipocytes and favor adipogenesis of stem cells [4-6]. The density of cells can also 
affect stem cell determination. When cultured human mesenchymal cells are plated in high 
cellular density, they are more likely to become adipocytes. At low densities the cells 
preferentially become osteoblasts [7]. Bone morphogenic protein-4 (BMP-4) is another potential 
regulator of the determination phase and is known to cause  preadipocyte formation ex vivo in the 
multipotent stem cell line C3H10T1/2 [8].  
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 Once a stem cell becomes a preadipocyte, the terminal differentiation phase begins. In 
culture, preadipocytes arrest at the G1/S phase of the cell cycle once enough cells amass to cause 
contact inhibition. This cell arrest phase is required for differentiation. After growth arrest, 
differentiation is induced by adding compounds such as methylisobutylxanthine, dexamethasone, 
and supraphysiologic doses of insulin to cultured cells [9]. There are many combinations of 
hormones and steroids that can be used for induction in vitro; however, mechanisms by which 
induction occurs in vivo are still unclear [5]. About 24 hours after induction, immature 
adipocytes will re-enter the cell cycle and undergo at least one round of mitosis and clonal 
expansion. After this stage, the transforming cells undergo a second phase of growth arrest 
termed GD. This phase of development appears to be mediated by C/EBPα and PPARγ and 
marks the moment of full preadipocyte commitment to becoming a mature adipocyte [5, 9]. 
C/EBPα and PPARγ are involved in activating adipose-specific genes, such as adiponectin and 
fatty acid binding proteins [10]. Over the next several days, the cells become larger and rounder 
as they begin to accumulate triglycerides and complete the differentiation process [9].  
Adipose Anatomy 
Mammalian adipocytes can be one of two forms: white or brown. White adipose tissue’s 
(WAT) main function is to store and release energy in the form of triglycerides. White 
adipocytes are large, unilocular cells filled with a droplet of lipid that pushes the cytoplasm and 
nucleus to the cell periphery. In contrast, brown adipocytes are made up of smaller, multilocular 
lipid droplets and contain large amounts of mitochondria. The purpose of brown adipose tissue 
(BAT) is to produce heat energy that can be distributed throughout the body. When an animal is 
cold, the sympathetic nervous system indirectly stimulates hypertrophy of BAT and up-regulates 
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uncoupling protein 1 (UCP1) in the mitochondria. UCP1 promotes reentry of protons into the 
mitochondrial matrix, uncoupling the transport of electrons from ATP synthesis through the 
respiratory chain. This uncoupling causes energy to be converted to heat instead of being stored 
as ATP [3, 11]. Substantial amounts of brown adipose tissue can be found in small mammals like 
rodents. Mammalian neonates also have brown adipose tissue depots that dissipate over time. 
Traditionally it has been assumed that brown adipose tissue mass is negligible in larger, mature 
mammals like human beings and cats [12, 13]; however, recent tumor imaging methods using 2-
[18F]-fluoro-2-desoxy-glucose (FDG) and computed tomography (CT) have revealed depots of 
brown adipose in mature humans. The prevalence of BAT in people receiving FDG CT scans 
varies widely from 10-80% of total fat mass [14, 15]. The discovery of BAT depots in adults has 
renewed research interest in this tissue as it relates to obesity. Nevertheless, the remainder of this 
discussion will focus on white adipose tissue unless otherwise noted. 
 As mentioned previously, adipose tissue is made up of more than just adipocytes. Both 
white and brown adipose tissue contain vascular and nervous supplies that comprise a 
stromovascular fraction. Individual adipocytes are supplied with a capillary and surrounded by a 
glycoprotein layer and reticular matrix [16]. Noradrenergic fibers of the sympathetic nervous 
system provide innervation to the tissue [17]. Other cells within the stromovasculature include 
preadipocytes, endothelial cells, fibroblasts, smooth muscle cells, macrophages, and white blood 
cells [16, 18].  
White adipose tissue can be placed into two broad anatomic categories: visceral adipose 
and subcutaneous adipose. Visceral adipose is the fat surrounding organs within the abdominal 
cavity. Excess visceral fat has been implicated in development of cardiovascular disease, insulin 
resistance, and the metabolic syndrome [19]. Fat located outside of a body cavity is considered 
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subcutaneous fat. Recently, further division of subcutaneous adipose tissue has been proposed 
[20].  Subcutaneous fat can be separated anatomically by stromal fascia into a deep and 
superficial layer. The expression of certain adipokines like leptin and resistin appear to be 
increased in deep compared to superficial subcutaneous fat [20]. Other adipose depots exist in 
areas such as the retroperitoneal space, but most research has focused on the visceral and 
subcutaneous regions. 
Endocrine Functions of Adipose 
 In addition to functioning as an energy storage site and thermal insulation, adipose tissue 
operates as an active endocrine organ. A variety of endocrine, paracrine, and autocrine signals 
are released from cells within adipose tissues. These signals are referred to as adipokines. 
Although many adipokines have been discovered, the function and physiologic relevance of most 
have not been identified. A handful of adipokines have been intensively studied and appear to 
positively or negatively impact insulin sensitivity. The metabolic role of most adipokines is 
complex and incompletely understood. For example, TNF-alpha is known to promote muscle 
turnover, fatty acid breakdown and cachexia in certain disease states, but also promotes insulin 
resistance during obesity [18]. The following are examples of adipokines thought to influence 
obesity-related insulin resistance. Ongoing research is needed to delineate their capacity to 
modify adiponectin levels and/or activity.  
Leptin 
 The name leptin is derived from the Greek word leptόs, meaning thin, because when the 
hormone is injected into leptin-deficient and normal mice it reduces food intake and body fat 
[21]. Presence of an obesity mutation (ob) was first discovered in mice nearly sixty years ago 
 6 
[22]. Mice with the ob/ob mutation in the leptin gene are morbidly obese, insulin resistant, 
hypothyroid,  infertile, and have defective T-cell immunity [23]. In 1994, this mutation was 
cloned, sequenced, and later found to code for the hormone leptin [24]. Leptin is a 16kDa protein 
that circulates freely or bound to other proteins [25].  Although secreted almost exclusively from 
adipocytes, small amounts are found in skeletal muscle, gastric fundic mucosa, placenta, and 
mammary epithelium [26]. 
Six isoforms of the leptin receptor have been identified (OBRa through OBRf) and are 
categorized as short, long, or secretory (Figure 1A). All of the leptin receptors are structurally 
similar to the class I cytokine receptor family [27, 28]. The short OBRa and OBRc isoforms are 
found in the choroid plexus and microcirculation of the nervous system and aid in leptin passage 
across the blood-brain barrier [29]. The soluble OBRe isoform does not contain a transmembrane 
domain and is secreted into circulation where it complexes with free leptin. The OBRe-leptin 
complex is thought to inhibit binding of leptin to its most influential receptor, OBRb [30]. OBRb 
is the long form receptor for leptin, and it contains an extended intra-cytoplasmic domain which 
activates several signal transduction pathways[23, 29]. OBRb receptor is distributed ubiquitously 
throughout the body with high concentrations in the hypothalamus [31].  
The interaction of leptin with its receptors activates several intracellular signaling 
pathways: Janus-activated kinase (JAK), signal transducers and activators of transcription  
(STAT), mitogen-activated protein kinase (MAPK), and insulin receptor substrate (IRS)[27]. 
The JAK/STAT signaling pathway is the most clearly described pathway. After leptin binds its 
receptor, activation of JAK leads to autophosphorylation of several tyrosine residues 
(Tyr1138,Tyr985, Tyr 974, and Tyr1077) on the OBRb receptor [31, 32]. Phosphorylated 
Tyr1138 attracts STAT3 to the OBRb-JAK complex where it is phosphorylated. STAT3 
 7 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1A: The six isoforms of the leptin receptor have the same extracellular  
ligand-binding domains but differ in their extracellular regions. Notice the soluble  
OBRe receptor lacks a transmembrane domain.  
Adapted from: Yang, R. and L.A. Barouch, Leptin Signaling and Obesity:  
Cardiovascular Consequences. Circ Res, 2007. 101(6): p. 545-559. 
 
Figure 1A: Leptin Receptor Isoforms 
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then translocates to the cell nucleus and begins to regulate transcription [27, 31, 32]. One of the 
transcription products of STAT3, suppressors of cytokine signaling 3 (SOC3), causes a negative 
feedback inhibition of leptin signaling. SOC3 binds to the phosphorylated tyrosines on the leptin 
receptor and impairs further signaling [31, 33]. This is one proposed mechanism behind the 
phenomenon of leptin resistance [29].  
Although increased levels of leptin should cause a reduction in body fat mass, obese 
individuals tend to have the highest levels of this hormone. When leptin becomes unable to 
effectively control and regulate appetite and energy expenditure, this is termed “leptin 
resistance” [34]. The consequences of leptin resistance were illustrated by a clinical study in 
which leptin had to be administered at a dose 20 to 30 times higher than normal physiologic 
levels to induce significant appetite reduction and weight loss in obese human subjects [35]. 
There are several mechanisms that may lead to leptin resistance: genetic mutation, receptor 
down-regulation, limited tissue access, and molecular interference [36]. While genetic mutations 
of leptin receptors can occur in human beings, they are a rare occurrence and account for only a 
tiny fraction of people with leptin resistance. Leptin is capable of self-regulating its physiologic 
action by down-regulating it receptors. A reduction in receptor numbers has been demonstrated 
in the hypothalamus of rodents that overexpress leptin [36]. In addition, prolonged increases in 
central leptin concentrations eventually diminish its physiologic actions [37]. Leptin resistance 
may also be the result of impaired entry of leptin across the blood-brain barrier. It is thought that 
leptin enters the CNS via a saturable, unidirectional system mediated by the Ob-Ra receptor. 
Hyperleptinemic mice and human beings have decreased cerebrospinal fluid to serum ratios of 
leptin [38, 39]. The impact of these findings on leptin resistance is still unclear. Regulating the 
amount of leptin entering the CNS may actually be a protective mechanism to prevent high 
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levels of central leptin from downregulating hypothalamic receptors [36]. Both intra and 
extracellular molecules are known to interfere with leptin action. Some important intracellular 
leptin modifiers are the suppressor-of-cytokine-signaling-3 (SOCS3) and protein tyrosine 
phosphatase 1B. These molecules inhibit the leptin JAK/STAT signaling pathway [40, 41]. 
Extracellular molecules can also alter leptin function. Serum leptin-interacting proteins (SLIPs) 
were first identified in 2006 and include C-reactive protein (CRP) and adipoprotein-J (APO-J 
[aka. clusterin]). CRP may induce leptin resistance by inhibiting binding of leptin to its receptor 
[36, 41]. More research is needed to identify other SLIP molecules and to understand their 
impact on leptin function and resistance. 
 The main physiologic role of leptin is to regulate body fat mass through appetite control 
and increased energy metabolism. As body fat mass increases, more leptin is secreted from 
adipocytes. The arcuate nucleus of the basomedial hypothalamus is the most recognized site for 
leptin action [32]. This region of the brain contains neurons that stimulate and suppress appetite. 
The neuropeptides agouti-related protein (AgRP) and neuropeptide Y (NPY) increase food 
intake and lower energy expenditure. Agouti-related protein works by antagonizing the 
melanocortin receptors (MC3R and MC4R) responsible for appetite suppression. Neuropeptide 
Y exerts its affects by acting on the paraventricular nucleus to increase appetite, decrease brown 
adipose tissue thermogenesis, and increase white adipose tissue lipoprotein lipase activity [42]. 
Leptin inhibits activity of neurons releasing NPY and AgRP, resulting in lower food intake. 
Furthermore, leptin activates anorexigenic neurons that release pro-opiomelanocortin (POMC). 
POMC can be post-translationally cleaved into several smaller products including the potent 
appetite suppressor, α-melanocyte stimulating hormone (α-MSH). α-MSH binds to the MC3R 
and MC4R receptors to induce anorexia [23, 43]. By stimulating POMC and suppressing AgRP 
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and NPY, increased leptin concentrations cause a reduction in appetite and an increase in energy 
expenditure in response to increased adipose tissue. 
 Although leptin’s primary physiologic role is to regulate body fat storage, it has a myriad 
of effects on the immune, cardiovascular, and reproductive systems. In addition, leptin may 
enhance insulin signaling and improve intracellular glucose uptake [44]. Leptin deficiency found 
in ob/ob rodents results in obesity, insulin resistance, and diabetes [45]. Administration of leptin 
to these mice and rats reverses the phenotype and improves insulin sensitivity [46, 47]. As 
mentioned earlier, one of the important intracellular signaling pathways activated by leptin 
involves insulin receptor substrates. Activation of JAK2 by bound leptin receptor leads to 
phosphorylation of insulin receptor substrate (IRS) proteins. The p85 regulatory subunit found 
on the IRS attracts and binds to phosphotidylinositol 3’-kinase (PI3K) [32, 33]. PI3K is involved 
in a variety of down-stream signaling events that ultimately lead to glucose entry into the cell. 
Leptin may also decrease accumulation of lipid in peripheral tissues. Lipid accumulation within 
cells can lead to the phenomenon of lipotoxicity (see discussion to follow). Administration of 
leptin has been shown to decrease cellular lipid stores in pancreatic, adipose, hepatic, and cardiac 
tissues [48]. 
Although there is evidence demonstrating positive effects of leptin on insulin sensitivity, 
there are also studies suggesting leptin has little effect on insulin’s performance or may even be 
detrimental to insulin signaling [49]. A recent in vitro study using murine cardiomyocytes found 
that incubation with leptin had no effect on insulin signaling but increased fatty acid uptake and 
decreased fatty acid oxidation in the mitochondria. This could result in lipotoxicity and actually 
impair insulin signaling [50]. Leptin also inhibits insulin action in hepatocytes, adipocytes and 
myocytes [51]. The paradoxical effects of leptin on insulin sensitivity may be due in part to 
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selective leptin resistance. Centrally, leptin appears to facilitate whole-body glucose disposal by 
stimulating satiety, increasing energy expenditure, and affecting the autonomic nervous system. 
If central effects of leptin were blunted and overall leptin levels were increased, the insulin-
inhibiting effects on peripheral tissue would become more prominent. This idea is supported by 
the fact that many in vitro studies find detrimental effects of leptin on insulin action while in vivo 
studies indicate leptin has an insulin-sensitizing role [52]. 
 Leptin influences the innate and adaptive immune systems. It stimulates a variety of cells 
including dendritic cells, monocytes, macrophages, and neutrophils. Leptin facilitates 
macrophage production of immune mediators such as nitric oxide, cholesterol acyl-transferase-1 
(ACAT), and cyclo-oxygenase 2 (COX-2), and leukotriene B4 [31, 53, 54]. In the adaptive 
immune system, leptin aids in thymic maturation and homeostasis [55]. In addition, studies of 
ob/ob and db/db mice have shown that leptin plays an important role in T and B cell maturation 
and survival [31, 56, 57]. The role of leptin in the cardiovascular system is complex and 
controversial.  High levels of leptin are associated with hypertension and congestive heart failure 
in people. Animal and rodent models also indicate leptin contributes to atherosclerosis via 
endothelial dysfunction [27].  
Leptin contributes to hypertension through stimulation of the sympathetic nervous 
system, generation of reactive oxygen species (ROS) in endothelial cells, and promotion of 
tumor necrosis factor – alpha (TNF-α) and interleukin-6 (IL-6) secretion [27, 58, 59].  In 
addition, leptin stimulates release of the potent vasoconstrictor endothelin-1 [60]. The OBRb 
leptin receptors have been identified on vascular endothelial cells, and this suggests a direct role 
of leptin in development of atherosclerotic lesions [61, 62].  Leptin indirectly induces oxidative 
stress in endothelial cells and vascular smooth muscle cells which leads to cell damage. Injured 
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cells release factors such as monocyte chemoattractant protein-1 and endothelin-1 that enhance 
the adhesion and infiltration of macrophages, lymphocytes, and lipid deposits into the vessel wall 
[27, 28]. Within vascular smooth muscle cells leptin increases cell migration, proliferation, and 
hypertrophy via phosphatidylinositol 3-kinase activity [27, 28, 63].  
Leptin interacts with several other adipokines. It has a reciprocal relationship with TNF-α 
and IL-6 and promotes expression of these inflammatory adipokines while they increase leptin 
expression [64]. Leptin is reported to suppress the expression of resistin and increase the 
expression of adiponectin in leptin-deficient mice [64-66]. 
Feline Leptin 
 
 While research regarding feline leptin is a small fraction of the data available in human 
beings and rodents, results are consistent with other species. A search through the National 
Center for Biotechnology Information GenBank shows that feline leptin has a similar amino acid 
length to human beings (146 compared to 167) [67]. The feline leptin sequence is also 
homologous to other species; 92% with dogs, 86% with human beings, and 82% with mice 
(Figure 1B) [67]. Leptin correlates positively with body fat mass in cats [68-72], and appears to 
correlate positively with insulin resistance, independent of adiposity [73]. The average level of 
leptin in lean, healthy cats is about 6.4 +/- 2.2 ng/ml of human equivalents (HE) [74]. When 
research cats were allowed to gain an average of 44% of their body weight, mean leptin levels 
tripled from 7.9 ng/ml to 24.5 ng/ml [74]. One particularly interesting facet to this study was the 
observation that obese cats with high levels of leptin continued to eat and gain weight. This 
suggests that leptin resistance also occurs in cats. 
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Tumor Necrosis Factor – alpha 
 Tumor necrosis factor-alpha (TNF-α) is an inflammatory cytokine expressed by a variety 
of cells including macrophages, mast cells, neuronal cells, fibroblasts, and adipocytes. The 
connection between TNF-α, obesity, and insulin resistance is unclear. Since TNF-α can be 
secreted by both differentiated and undifferentiated adipocytes, it was thought that the increased 
levels of TNF-α found in obesity were primarily due to adipocyte secretion; however, cells 
within the stromovascular fraction of adipose tissue, including macrophages, produce 
significantly more TNF-α than adipocytes [18, 75, 76]. Obesity increases macrophage migration 
into adipose tissue, and this is likely the cause of increased TNF-α expression [77, 78]. One 
theory behind recruitment of monocytes and macrophages to expanding adipose tissue is that 
increased levels of adipocyte apoptosis and necrosis produce chemoattractant agents [18, 79]. 
 TNF-α secretion from adipose tissue has key species differences. In mice, TNF-α is 
released into systemic circulation [79]. In human beings, most adipose TNF-α exerts local 
paracrine and autocrine actions [80, 81]. Although the circulation patterns of TNF-α derived 
from adipose tissue are not well understood in cats, mRNA expression within fat is increased 
with obesity [82]. Two cell surface receptors mediate TNF-α’s effects on adipose tissue: tumor 
necrosis factor-alpha receptor 1 (TNFR1) and tumor necrosis factor-alpha receptor 2 (TNFR2). 
Both of these receptors are transmembrane proteins expressed throughout the body [18]. One of 
the primary actions of adipose TNF-α is induction of localized insulin resistance. TNF-α down 
regulates genes responsible for insulin receptor, glucose transporter-4 (GLUT-4), and insulin 
receptor substrate-1 (IRS-1) expression [83, 84]. TNF-α also inhibits the transcription factors 
PPAR-γ and CCAAT-enhancer-binding proteins that regulate insulin sensitivity [85]. In addition 
to inhibiting glucose entry into adipocytes, TNF-α decreases uptake of free fatty acids (FFA) into 
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adipocytes. Fatty acid transport protein (FATP), translocase, and the fatty acid binding protein 
FABP4/aP2 are important mediators of fatty acid uptake that are down regulated by TNF-α [18, 
86]. TNF-α also impairs triglyceride storage in adipose tissue by inhibiting proteins involved in 
de novo FA synthesis, glyceroneogenesis, and esterification. Transcription and expression of 
these proteins is regulated by PPARγ, which is also inhibited by TNF-α [18]. Another important 
action of TNF-α in adipose tissue is induction of lipolysis and release of FFA into circulation 
[80]. This, combined with impaired FA uptake and storage by adipocytes, leads to increased 
levels of FFA in circulation and negatively effects insulin sensitivity in peripheral tissues. A 
more in-depth discussion of fatty acids and insulin sensitivity can be found under the lipotoxicity 
heading below.  
 In addition to directly influencing insulin sensitivity of adipose tissue, TNF-α can alter 
secretion of other adipokines involved in glucose metabolism. In particular, TNF-α inversely 
correlates with adiponectin and may alter its gene expression by suppressing the transcription 
factors PPAR-γ and CCAAT/enhancer binding protein-beta (C/EBP) while activating c-Jun N-
terminal kinase (JNK) [18, 80, 87, 88]. In contrast to adiponectin, expression of resistin, leptin, 
and visfatin is increased by TNF-α [64]. In summary, TNF-α secreted from adipose tissue plays 
an important role in glucose and lipid metabolism at both the local and systemic level and is a 
key component to inflammation associated with obesity.  
Resistin 
 The adipocyte-derived hormone resistin was discovered by three independent researchers 
in 2000 and 2001 [89-91]. The physiologic roles of resistin are debated. Studies in rodent models 
suggest resistin is involved in regulation of metabolism, adipogenesis, and inflammation [92]. 
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Specifically, resistin impairs insulin sensitivity and predisposes rodents to Type-2 diabetes [66, 
89, 93]. Unfortunately, resistin research in rodents has not translated well to human beings. 
There are key differences between resistin biology in human beings and mice that may explain 
its inconsistent action. First, there is only a 59% and 64.4% homology of the amino acid and 
mRNA sequences [92, 94]. Second, the source of resistin is very different between human beings 
and mice. Mice secrete the hormone almost exclusively from white adipose tissue [92]. Human 
beings express resistin mostly in the bone marrow and lungs, with adipose levels being nearly 
undetectable [95]. Macrophages and monocytes appear to be the main cell types that produce 
resistin in human beings [96]. Studies evaluating resistin’s relationship to obesity and diabetes in 
human beings are conflicting [93]; however, resistin appears to act as a proinflammatory 
mediator and may contribute to atherosclerosis [97, 98]. Information regarding restin’s 
interactions with other adipokines is sparse, but the adipokine may increase expression of TNF-α 
and IL-6 [64]. Leptin also increases resistin expression in leptin deficient mice[66]. 
Visfatin 
 
The protein pre-B-cell colony enhancing factor (PBEF) was first discovered in human 
lymphocytes nearly 15 years ago [99]. PBEF was later shown to be expressed in adipocytes, 
particularly visceral adipose cells. As a result, PBEF was renamed visfatin [100]. Although 
adipocytes release visfatin, most of the hormone is secreted from macrophages within adipose 
tissue [101]. Initial research showing visfatin is secreted predominately from visceral fat was 
challenged in a later study finding equal mRNA expression between subcutaneous and visceral 
adipose depots [100, 102].  Although some rodent studies suggest visfatin has insulin-like 
activity and contributes to the pathogenesis of diabetes, clinical studies in people have been 
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contradictory [103]. In particular, studies correlating visfatin with body mass index are 
conflicting [102, 104]. There is also inconsistent data relating visfatin to insulin sensitivity and 
diabetes [105-107]. Similar to restin, visfatin’s impact on other adipokines such as adiponectin is 
not clear, but it appears to increase expression of TNF-α and IL-6 [64]. 
Interleukin-6 
 
 Interleukin-6 (IL-6) is pleiotropic cytokine affecting a wide variety of physiologic 
processes. It plays a major role in regulating inflammation, immune responses, and 
hematopoiesis [108]. IL-6 appears to mirror TNF-α in its interactions with other adipokines. It 
has an inhibitory effect on adiponectin and promotes expression of leptin, resistin, and visfatin 
[64]. IL-6 initiates cell signaling by binding its membrane-bound receptor (IL-6r) or its cleaved, 
soluble receptor (sIL-6r) [109]. Similar to leptin, IL-6 uses the JAK-STAT pathway and MAPK 
cascade to alter transcription and produce the family of proteins called suppressors of cytokine 
signaling (SOCS) [109, 110]. SOCS inhibit insulin signaling pathways by inhibiting tyrosine 
phosphorylation of insulin receptor substrate (IRS) proteins through competitive inhibition of the 
insulin receptor, inducing degradation of IRS, and by inhibiting insulin receptor kinase [111]. 
Although IL-6 is  secreted from an array of cell types, it’s secretion from adipocytes will be the 
focus of this discussion. 
Adipose tissue secretes up to 35% of basal IL-6 plasma levels [81]. Although adipocytes 
produce IL-6, other cells in the stromovascular fraction also secrete the cytokine and probably 
contribute more to overall secretion [108, 112]. Visceral adipose tissue secretes more IL-6 than 
subcutaneous adipose, and the concentration of IL-6 in adipose tissue is approximately 100-fold 
greater than that of plasma [112, 113]. This implies IL-6 plays an autocrine and/or paracrine role 
 19 
in adipose. One important function may be to induce lipolysis within adipocytes. Adipocytes and 
adipose tissue grown in culture with IL-6 demonstrate increased levels of lipolysis [108, 114]. In 
addition, infusion of IL-6 in humans increases overall fatty acid concentration and oxidation 
[108, 115, 116].   
 Several studies demonstrate a positive relationship between IL-6 adipose expression and 
insulin resistance [109, 117, 118]; however, a cause and effect relationship has not been 
established, and higher concentrations of IL-6 may only reflect increased adipocyte numbers. 
Studies showing IL-6 closely correlates with body mass index (BMI) but not insulin sensitivity 
in healthy and diabetic patients support this idea [119, 120]. Some of the confusion regarding IL-
6’s contribution to insulin sensitivity may be due to its conflicting action on the skeletal muscle, 
liver, and fat. In general, IL-6 appears to improve insulin’s action in skeletal muscle while 
impairing insulin-mediated glycogen synthesis and glucose uptake in hepatic and adipose tissue, 
respectively [108].  
Adiponectin 
 
Discovery 
 Adiponectin is an adipokine secreted almost exclusively from adipocytes. It was 
discovered in 1995 and 1996 by four independent research groups [121-124]. Since adiponectin 
was identified by several researchers, multiple names for the hormone are found in the literature. 
These include AdipoQ, adipocyte complement-related protein of 30 kilodalton (Acrp30), adipose 
most abundant gene transcript 1 (apM1), and gelatin-binding protein of 28 kilodalton (GBP28) 
[125]. The name AdipoQ came from Hu et al.’s discovery of adiponectin using mRNA 
differential display with cultured murine fibroblastic cells and pre-adipocytes [121]. Schrerer et 
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al. used a similar technique in their discovery of adiponectin and coined the term Acrp30 [124]. 
Maeda et al. performed large scale random sequencing of the human adipose cDNA library. 
When they noticed a partial cDNA sequence with abundant transcripts they discovered the 
protein apM1 and coined the term adiponectin [122]. Finally, GBP28 was discovered by Nakano 
et al. using gelatin affinity chromatography to identify novel plasma proteins which bind 
collagen fibers [123]. The term adiponectin will be used in this discussion.  
Structure  
Adiponectin is a 247 amino acid protein with a molecular weight of approximately 28 
kda [124]. The gene encoding adiponectin maps to chromosome 3q27 in human beings. This 
chromosome also contains a diabetes susceptibility locus [126]. The amino acid sequence of 
adiponectin can be divided into four domains. First is the amino-terminal sequence, followed by 
a variable 27 amino acid region. The third region is a collagenous domain made up of 22 Gly-X-
Pro (8) and Gly-X-Y (14) repeats [123, 124]. Finally, the carboxyl-terminal end makes up a 
globular domain that is homologous to type VIII and type X collagens and complement factor 
C1q [124, 126]. The crystalline structure of adiponectin is similar in appearance to the TNF 
family of molecules [127].  
While the monomeric form of adiponectin is only about 28 kda, the protein almost 
always circulates in one of three multimeric forms (Figure 1C). Several techniques have been 
employed to measure adiponectin’s forms including size exclusion chromatography, velocity 
sediment analysis, non-reducing/non-heat denaturing sodium dodecylsulfatepolyacrylamine 
(SDS) gel electrophoresis, antibody affinity columns, and ELISA [128, 129]. Trimers of 
adiponectin molecules make up the low molecular weight (LMW) multimer (≈100kDa). LMW 
multimers can circulate as a full-length form or small amounts of the adiponectin molecules 
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Figure 1C: Illustration of adiponectin multimerization. Three monomers combine at their 
globular domains to form a trimer. The trimers then pair through disulfide bonds to make 
hexamers. Non-covalent higher-order interactions form the high molecular weight 
multimers.  
Adapted from: Oh, D.,Ciaraldi, T., and Henry, R. Adiponectin in health and disease. Diab 
Obes Metab. 2007, 9(3): 282-9. 
 
Figure 1C: Multimeric Forms of Adiponectin 
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can be proteolytically cleaved below the globular region to form trimers of the globular domains 
[130] . The full-length LMW form can readily bind to albumin through disulfide bonds [128]. A 
middle molecular weight (MMW) hexamer (≈180 kDa) consists of two LMW molecules bound 
together by disulfide bonds on the cysteine residues of their N-terminus [131]. The MMW form 
can be difficult to differentiate from the LMW-albumin complex that is approximately 160 kDa 
[128]. The high molecular weight (HMW) form of adiponectin is made up of twelve or more 
adiponectin molecules bound together. HMW adiponectin binds to AdipoR1 in myocytes and 
phosphorylates AMPK more effectively than LMW and MMW forms of the protein, leading to 
increased glucose uptake by the cells [128].  Also, lower concentrations of the HMW form is 
more closely associated with insulin resistance and diabetes than total adiponectin or the lower 
weight forms [132, 133]. 
Secretion and regulation 
Adiponectin is the most abundantly secreted adipokine in circulation with concentrations 
in the µg/ml range (three orders of magnitude higher than leptin) [129]. Adiponectin is secreted 
almost exclusively from adipocytes; however, small amounts of adiponectin are secreted by 
preadipocytes in bone marrow [134], osteoblasts [135], cultured cardiac myocytes [136], and 
portal endothelial cells [137], placental tissue [138], and  pituitary cells [139]. Adiponectin is 
synthesized in the endoplasmic reticulum and stored in vesicles within the Golgi apparatus or 
trans-Golgi network under steady-state conditions[140, 141]. The method of trafficking 
adiponectin from the Golgi to the cell membrane remains unclear.  
  Although adipocytes are responsible for secreting adiponectin, hormone levels become 
paradoxically lower with increased fat mass [142]. The reason behind this unusual relationship is 
not clear. It is speculated that increased levels of other adipokines, such as TNF-α, may suppress 
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adiponectin expression. Although regulation of adiponectin gene expression is poorly 
understood, many factors appear to influence its activation (Figure 1D). Within the promoter 
region of the human and mouse adiponectin genes there are binding sites for transcription 
factors. These include peroxisome proliferator-activated receptor (PPAR) responsive element 
(PPRE), sterol regulatory elements (SREs), CCAAT enhancer-binding protein  sites, and E-
boxes [143, 144]. The PPRE promoter is the best characterized for adiponectin. PPRE binds with 
PPAR’s to initiate transcription of certain genes. PPARγ activates many adipose-specific genes 
and plays a key role in adipocyte differentiation by stimulating factors promoting fatty acid 
storage. Examples of such gene products include: lipoprotein lipase, fatty acid binding protein, 
phosphenol pyruvate carboxykinase, and acyl-CoA synthase. PPARγ also inhibits adipokines 
involved in lipolysis such as leptin and TNF-α [145]. Activation of PPARγ occurs endogenously 
by free fatty acids and eicosanoids. A class of insulin-sensitizing drugs called thiazolidinediones 
(TZD) also bind to PPARγ and increases its activity [146]. TZD’s increase the secretion of 
adiponectin through PPARγ activation [147].  Omega-3 fatty acids, docosahexaenoic acid 
(DHA) and  eicosapentaenoic acid (EPA), promote translation of adiponectin in vitro through 
stimulation of PPARγ [148]. Supplementation conjugated linoleic acid and omega-3 fatty acids 
increases adiponectin concentrations in young men [149]. 
Although transcription factors are a key component to adiponectin production, mRNA 
expression does not always correlate well with serum concentrations. This is probably due to 
extensive post-transcriptional and post-translational modifications regulating adiponectin 
production. Following translation, adiponectin undergoes hydroxylation of proline and lysine 
residues and glycosylation of hydroxylysines [150]. Trimers of adiponectin are also combined  
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Figure 1D: Factors Regulating Adiponectin  
Figure 1D: Summary of factors that regulate adiponectin concentrations in humans. 
Controversial data is expressed with question marks.  
Adapted from: Swarbrick, M. and P. Havel, Physiological, pharmacological, and 
nutritional regulation of circulating adiponectin concentrations in humans. Metab 
Syndr Relat Disord, 2008. 6(2): p. 87-102. 
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via disulfide bonds to form large molecules. Adiponectin molecules of different sizes influence 
the expression of intracellular chaperone proteins such as Ero1-Lα and ERp44 to increase or 
decrease adiponectin’s release from cells [151]. 
While PPARγ plays an instrumental role in adiponectin expression, several other factors 
also influence secretion of the hormone. Acute insulin administration increases the secretion of 
adiponectin [152]; however, more chronic administration of insulin gives conflicting results 
[153, 154]. Insulin-like growth factor-1 (IGF-1) also increases adiponectin gene expression in 
vitro while glucocorticoids, IL-6, and TNF-α decrease expression [125, 153-155]. In support of 
TNF-α’s role in modulating adiponectin, a new insulin sensitizer, I kappa B kinase beta 
(IKKbeta) inhibitor, increases adiponectin independent of body mass in mice.  This drug blocks 
TNF-α-induced reduction of adiponectin and increases insulin-stimulated Akt activity in vitro 
[156].  
As discussed earlier, subcutaneous and visceral adipose depots differ in their secretion of 
certain adipokines. Subcutaneous adipose tissue secretes 25-60% more adiponectin than visceral 
adipose in human beings [157-159]. In addition, adiponectin negatively correlates with visceral 
adiposity [160]. Adiponectin exerts beneficial effects in the body, and decreased hormone levels 
may contribute to insulin resistance and the increased risks of diabetes and cardiac disease 
associated with visceral obesity.  
Adiponectin serum concentrations are influenced by androgens and estrogens in people 
and rodents [129]. In human beings, females usually have higher levels of adiponectin than 
males [142, 161]. Females also have higher proportions of HMW adiponectin [162]. Evidence 
that male hormones lower adiponectin levels is found in studies of immature boys and castrated 
mice. As pre-pubescent boys mature, adiponectin levels decrease [163]. Neonatal castration of 
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male mice results in adiponectin concentrations similar to female mice, and ovariohysterectomy 
of female mice raises adiponectin concentrations[164]. Incubation of adipocytes with human 
male versus female serum decreases adiponectin mRNA expression [165]; however, when these 
cells were incubated with testosterone or estradiol there were no significant changes in 
adiponectin mRNA or protein expression. The ratio of HMW to LMW adiponectin was also 
unaffected. Testosterone negatively impacts adipocyte differentiation, and this may influence 
adiponectin by inhibiting preadipocyte maturation. In addition, the impact of sex hormones on 
adiponectin could occur at the post-translational level, or unidentified gender factors other than 
testosterone or estradiol may impact adiponectin production [165]. 
Adiponectin exhibits little diurnal variation in human beings. Fluctuations in plasma 
concentrations remain within about 20% of the 24-hour mean. However, levels decline slightly at 
night and a nadir occurs in early morning [166]. Adiponectin concentrations do not change 
significantly with meal consumption. Infusion of glucose IV and consumption of glucose-
containing meals did not influence adiponectin in normal weight, insulin sensitive individuals 
[150]. Short-term caloric restriction also does not impact adiponectin. Obese women consuming 
only 550 kcal/day for three weeks lost about 5% of their body weight, but did not change their 
adiponectin concentrations [167]. Other studies evaluating short-term caloric restriction in both 
men and women have similar results [150]. Exercise, independent of weight loss, also does not 
alter adiponectin concentrations [168-170].  
Receptors 
Two receptors for adiponectin have been identified to date, AdipoR1 and AdipoR2 [171]. 
A third potential receptor, T-cadherin, has also been associated with the cardiovascular system 
[172]. Although AdipoR1 and AdipoR2 can be found throughout the body, they are more 
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concentrated in skeletal muscle, adipose tissue, liver, pancreas, and hypothalamus [173-175]. 
Both adiponectin receptors contain 7 trans-membrane domains and are similar in structure 
(Figure 1E)[176]. AdipoR1 is found predominately in skeletal muscle and AdipoR2 is more 
concentrated in the liver [177].  Studies administering adiponectin in its full-length form and in 
the globular form demonstrate AdipoR1 has high affinity for globular and an intermediate 
affinity for full-length  adiponectin in skeletal muscle [176]. AdipoR2 has an intermediate 
affinity for both forms of adiponectin in the liver [178]. A recent study by Bjursell, et al. using 
adiponectin receptor knock-out mice suggests that AdipoR1 and AdipoR2 may have opposing 
effects on metabolism [171]. AdipoR1 knockouts were obese and glucose-intolerant while the 
AdipoR2 knockouts had improved glucose tolerance, decreased plasma cholesterol levels, and 
were resistant to diet-induced obesity. Differences between the two groups were attributed to 
changes in activity and energy expenditure [171]. Adiponectin has the ability to cross the blood-
brain barrier, and both adiponectin receptors are expressed in the hypothalamus [179]. The 
mechanism for adiponectin transport into the central nervous system is still unclear, but active 
transporters do not appear to be involved and the there may be intrathecal production of 
adiponectin [180].  
Metabolic actions 
Adiponectin exerts a myriad of metabolic affects. Perhaps the most influential role of 
adiponectin is as an insulin sensitizer. Adiponectin is closely associated with insulin sensitivity, 
independent of body fat mass [181-183]. In a study of obese rhesus monkeys, low adiponectin 
levels correlated with insulin resistance and preceded the onset of diabetes mellitus [184].  
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Figure 1E: Illustration of adiponectin receptors. Note the similarities in general structure and 
the 7 transmembrane domains. 
Adapted from: Méndez-Sánchez et al. Adiponectin, structure, function and pathophysiological 
implications in non-alcoholic fatty liver disease. Mini-Reviews in Medicinal Chemistry, 2006; 
6 (6). 651-656. 
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Prospective and longitudinal studies in human beings also demonstrate lower adiponectin levels 
are closely associated with insulin resistance and future development of diabetes [185-187].  
Higher levels of adiponectin are also strongly associated with reduced risk of Type-2 diabetes in 
healthy adult human beings [188].  
Adiponectin influences lipid and carbohydrate metabolism in skeletal muscle and hepatic 
tissue through activation of AMP-activated protein kinase (AMPK), p38 mitogen-activated 
protein kinase (MAPK), and PPAR-α. Activated adiponectin receptors transmit intracellular 
signals by interacting with the protein APPL1 [177]. The overall effect of adiponectin in the 
skeletal muscle is to lower triglyceride accumulations within the tissue and increase glucose 
uptake [146]. Adiponectin stimulates fatty acid oxidation by sequentially activating AMPK, p38 
MAPK, and PPAR-α [177, 189]. PPAR-α is a key regulator of fatty acid oxidation and p38 
MAPK phosphorylates and activates PPAR-α [190]. PPAR-α increases lipid metabolism by 
upregulating genes involved in lipid transport and oxidation, including fatty acid translocase 
(FAT/CD36) and acyl-CoA oxidase (ACO). FAT is a membrane glycoprotein important for 
fatty-acid transport, while ACO is a critical enzyme for beta-oxidation within peroxisomes [146, 
191]. 
Glucose uptake in skeletal muscle is improved by adiponectin’s activation of AMPK and 
the subsequent translocation of glucose transporter 4 (GLUT-4) [192]. AMPK is an important 
regulator of cellular energy. When energy is low, there is an abundance of adenosine 
monophosphate (AMP), rather than adenosine triphosphate (ATP). Rising levels of AMP 
stimulate AMPK to increase the cell’s ability to take in more glucose while releasing stored fats 
for energy [193]. By stimulating AMPK, adiponectin improves cellular glucose uptake while 
promoting fatty acid oxidation in skeletal muscle. 
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In the liver of people and rodents, adiponectin improves insulin sensitivity while reducing 
triglyceride content and gluconeogenesis. Adiponectin activates AMPK in hepatocytes and this 
activation suppresses gluconeogenesis by decreasing the expression of phosphoenolpyruvate 
carboxykinase (PEPCK) and glucose-6-phosphate [146, 177, 194, 195]. These two enzymes help 
convert oxaloacetate to phosphoenolpyruvate and glucose-6 phosphate to glucose, respectively. 
Adiponectin does not appear to affect glucose uptake, glycogen synthesis, or glycogenolysis in 
the liver [146]. 
 Adiponectin’s metabolic actions in skeletal muscle and the liver may also impact 
circulating levels of lipoproteins. Low levels of adiponectin are associated with dyslipidemia 
[196-198]. Increased levels of high density lipoprotein (HDL) cholesterol and lower levels of 
triglycerides and apolipoprotein (Apo) B-100 have been found with high concentrations of 
adiponectin. These relationships remain even after adjusting for obesity-related factors [196]. In 
the liver, HMW adiponectin suppresses the release of ApoB and ApoE (components of low 
density lipoproteins) while having no affect on Apo A (component of high density lipoproteins) 
[199]. 
 In addition to playing an important role in carbohydrate and lipid metabolism, 
adiponectin contributes to cardiovascular health in human beings and rodents [126]. 
Development and eventual disruption of atherosclerotic plaques in vascular endothelium of 
blood vessels results in ischemic injuries to the heart or other organs and leads to substantial 
morbidity and mortality. Low levels of adiponectin are associated with increased endothelial 
dysfunction [200]. Adiponectin prevents formation of atherosclerotic plaques through several 
mechanisms [126].  It increases production of the vasodilator nitric oxide [201], decreases 
expression of adhesion molecules on the endothelial surface that attract monocytes [202],  
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inhibits scavenger receptors on the surface of macrophages to lower uptake of oxidized LDL 
cholesterol [203], and exerts antithrombotic properties [204]. Although adiponectin decreases 
development of atherosclerotic lesions on a molecular and physiologic level, the clinical 
relevance of adiponectin in cardiovascular disease remains controversial [205]. 
Hypoadiponectinemia has been associated with coronary atherosclerosis and acute coronary 
syndrome [202, 206, 207]. In addition, low adiponectin levels have been shown to predict the 
degree of coronary atherosclerotic disease in German men [205, 208]; however, other studies in 
women and American Indians have not shown adiponectin to be a consistent predictor of 
cardiovascular disease [209, 210]. A prospective study combined with a meta-analysis of 
previous research showed only a moderate association between adiponectin and cardiovascular 
disease [211].  
 While it is well established that adiponectin improves insulin sensitivity and may protect 
against cardiovascular disease, a new role for adiponectin in the regulation of appetite has 
recently been proposed. Adiponectin receptors AdipoR1 and AdipoR2 are both found in the 
hypothalamus of mice in close proximity to leptin receptors, and low concentrations of 
adiponectin are present in cerebrospinal fluid (CSF). Interestingly, only the LMW and MMW 
forms of adiponectin are detectable in CSF of wild-type mice. In mice, serum and CSF 
adiponectin concentrations fall in the postprandial state and rise during fasting. The expression of 
AdipoR1 in hypothalamus also decreases after feeding [179]. Binding of adiponectin to AdipoR1 
in the arcuate hypothalamus stimulates food intake in mice and lowers energy expenditure [175]. 
These findings lead to the hypothesis that adiponectin works in coordination with leptin to 
regulate food intake. In the post absorptive state, adiponectin activates hypothalamic AMPK and 
food intake is stimulated while energy expenditure is slowed. In the postprandial state, leptin 
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signaling in the hypothalamus dominates and AMPK activity decreases. This results in appetite 
suppression and increased energy output [179]. While this theory is intriguing, more work is 
needed to determine how obesity affects adiponectin signaling in the hypothalamus.    
Feline Adiponectin 
 
Research regarding adiponectin in cats is still in its infancy. To date, only two articles are 
referenced through the National Center for Biotechnology Information (NCBI) PubMed 
database. Hoenig et al. demonstrated serum adiponectin concentrations correlate inversely with 
body mass as cats gain and lose weight [72]. Another study demonstrated adiponectin is secreted 
from both visceral and subcutaneous adipose [212]. The complete nucleotide sequence for feline 
adiponectin is available on NCBI GenBank. The amino acid sequence of feline adiponectin is 
90%, 84%, and 86% homologous to the dog, human being, and mouse, respectively.   
Indirect evidence regarding adiponectin’s function in the cat is derived from research 
evaluating the use of a TZD called darglitazone. In human beings, TZD’s activate PPARγ and 
increase the secretion of adiponectin. Darglitazone treatment in obese cats lowered cholesterol, 
triglyceride, and leptin when compared to placebo-treated cats. There was also a significant 
decrease in the area under the curve for non-esterified fatty acids, glucose, and insulin during 
intravenous glucose tolerance testing [213]. These results are consistent with TZD administration 
in humans and may indicate that adiponectin behaves similarly in these two species. 
Role of Insulin in Metabolism 
Insulin impacts metabolism of carbohydrates, proteins, and lipids through its actions on a 
variety of tissues. The principal metabolic roles of insulin will be described to facilitate a better 
understanding of insulin resistance and its pathologic consequences. The physiologic 
descriptions found below come primarily from human and laboratory animal research. Cats 
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differ from most other species in several key metabolic pathways, and an evaluation of these 
differences will follow the general discussions. 
Insulin Secretion and Regulation 
 
 Insulin is an anabolic hormone that promotes storage of proteins, lipids, and 
carbohydrates. It is produced and secreted from beta cells in the islets of Langerhans within the 
pancreas. The rough endoplasmic reticulum of beta cells produces insulin and the Golgi 
apparatus packages the hormone into membranous granules which are expelled from the cell 
surface by exocytosis [214, 215]. The formation of insulin begins with synthesis of a larger 
preprohormone. Preproinsulin is a 23-amino-acid peptide that is cleaved, and the remaining 
molecule is folded to form proinsulin. Two peptide chains (A and B) make up proinsulin and are 
bound together by a third chain, connecting (C) peptide. The C peptide facilitates folding of 
proinsulin and is removed from the granules before insulin is secreted. C peptide is secreted in an 
equal ratio with insulin and is an alternative method for measuring insulin concentrations [215].  
Insulin secretion is affected by a number of factors. A primary regulator of insulin 
secretion is glucose. There are two pathways by which glucose stimulates the release of insulin 
from the beta cell: K+ -ATP channel-dependent and K+-ATP channel-independent pathways 
[216]. Glucose transporter protein-2 (GLUT-2) facilitates glucose entry into the pancreatic beta 
cell. Glucose is rapidly phosphorylated by glucokinase and is then metabolized to ATP, carbon 
dioxide, and water via glycolysis and the citric acid cycle. In the K+ATP channel-dependent 
pathway, accumulation of ATP in the cell cytoplasm inhibits ATP-sensitive K+ channels and 
decreases K+ efflux from the cell. The increased number of cations causes the cell to depolarize. 
As a result, voltage-gated Ca 2+ channels open and allow an influx of Ca 2+. Increased 
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intracellular Ca 2+ triggers exocytosis of secretory granules containing insulin and causes and 
immediate spike in insulin release. Release of insulin in response to glucose is biphasic. The first 
phase is a rapid, transient spike that is mediated by calcium influx. The second phase, directed by 
the K+ATP channel-independent pathway, is slower to develop and lasts longer. Although the 
vast majority of insulin (>95%) is released during the second phase response, details of this 
pathway are still unclear [214]. One possibility is that glucose metabolism increases the 
concentration of intracellular malonyl CoA which decreases fatty acid oxidation. Long-chain 
fatty acids accumulate and may directly or indirectly signal insulin exocytosis. Other potential 
mediators include glutamate, the pyruvate-malate shuttle, and increased ATP/ADP ratio [217]. 
The receptor for insulin is a tyrosine kinase made up of four subunits. On the 
extracellular surface two α-subunits act as the site for insulin binding. These peptides are linked 
with two β-subunits that span the cell membrane. The details of insulin receptor signaling are 
complex and beyond the scope of this dissertation, and a more detailed review is provided by 
Karlsson and Zeirath [218]. Briefly, when insulin binds to its receptor, autophosphorylation 
occurs causing conformational changes that activate tyrosine residues found in the intracellular 
portions of the β-subunits. These activated tyrosines provide binding sites for several down-
stream signaling molecules [219, 220]. The most extensively researched signaling molecules 
belong to the insulin receptor substrate (IRS) family of proteins.  IRS proteins bind to the 
activated insulin receptor and in turn recruit and activate other enzymes. One of the most notable 
of these enzymes is phosphatidylinositol 3-kinase (PI-3K). PI-3K is involved in the production of 
other intermediaries that bind to the pleckstrin homology (PH) domain of Akt/protein kinase B 
(PKB). PKB is a key regulator of glucose uptake and essential for GLUT-4 translocation to the 
cell membrane [221].  
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Carbohydrate Metabolism 
 
 Dietary carbohydrates are primarily polymers of hexoses such as fructose, galactose, and 
glucose. Glucose is the main sugar found in circulation and normal fasting venous levels in 
human beings range from 70-110mg/dl [222]. Circulating glucose comes from the ingestion of 
carbohydrates or from gluconeogenesis and glycogenolysis. Glucose enters cells either through 
secondary active transport with sodium/glucose symporters (SGLT) or by facilitated diffusion 
with glucose transporter proteins (GLUT) [223]. SGLT 1 and SGLT 2 are predominately found 
on the intestinal brush border and renal tubules and play important roles in glucose absorption 
[215]. Over 10 isoforms of GLUT receptors have been identified, but not all facilitate glucose 
entry into cells. GLUT-4 receptors are unique because they are stimulated by insulin and 
exercise to increase glucose uptake in skeletal muscle and adipose tissue [224]. Quantitatively, 
skeletal muscle is the most influential tissue for removal of post-parandial glucose [225]. 
Therefore, skeletal GLUT-4 receptors are critical for insulin’s regulation of blood glucose 
concentration. These receptors reside within intracellular vesicles and are stimulated to insert 
into the plasma membrane by exercise, hypoxia, or the binding of insulin to its receptor [219]. 
Glucose uptake within hepatocytes is mediated by GLUT-2 receptors which are not insulin 
sensitive [226]. 
 Insulin affects hepatic carbohydrate metabolism by inhibiting production of glucose 
while stimulating synthesis of glycogen. Under normal physiologic conditions,  
high levels of insulin accompany a carbohydrate-containing meal. When dietary glucose is 
plentiful, insulin prevents the liver from making more glucose and stimulates glucose 
storage in the form of glycogen. When insulin levels are low, such as in a fasting state, its 
suppressive effects on the liver are reversed and glucose is produced and released. Insulin 
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suppresses gluconeogenesis by inhibiting two critical enzymes: phosphoenolpyruvate 
carboxykinase (PEPCK) and glucose-6-phosphatase. PEPCK is needed for the rate-limiting step 
converting oxaloacetate to phosphoenolpyruvate, and glucose-6-phosphatase is required for 
dephosphorylation of glucose-6-phosphate to glucose. High levels of circulating glucose, 
glucocorticoids, glucagon, and the hypothalamus can also alter hepatic gluconeogenesis [226].  
Lipid Metabolism 
 
 Dietary free fatty acids (FFA) are converted to triacylglycerols and packaged into 
chylomicrons within intestinal enterocytes. Chylomicrons are apo B-48-containing lipoproteins 
rich in triglycerides and travel via the lymphatic circulation to the thoracic duct into systemic 
circulation. On the surface of endothelial cells, lipoprotein lipase (LPL) hydrolyses the 
triacylglycerol in chylomicrons into FFA. The fatty acids can be taken up and stored by 
adipocytes or oxidized by myocytes. Chylomicron remnants then travel to the liver where they 
bind to the low-density lipoprotein (LDL) receptor or LDL receptor-related protein and are 
removed from circulation. Very-low density lipoproteins (VLDL) are synthesized in the liver and 
packed with triglyceride. They contain the apo B-100 surface protein. VLDL molecules are also 
hydrolyzed by LPL. VLDL remnants (aka. intermediate-density lipoproteins (IDL)) can be taken 
up by liver receptors or converted to low-density lipoproteins (LDL). Chylomicrons, VLDL, 
LDL, and IDL make up the triacylglycerol-rich lipoproteins (TRL) [227].  
 During post-parandial situations, high levels of insulin inhibit lipolysis. Hormone-
sensitive lipase activity (HSL) is suppressed by insulin, resulting in retention of triglyceride 
stores in adipose and muscle. In addition, high levels of intracellular glucose in the fed state 
increase malonyl Co-A concentrations and suppression of carnitine palmitoyltransferase I and 
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fatty acid oxidation [225]. When adipose tissue is resistant to the action of insulin, HSL is no 
longer suppressed and fatty acids are released into circulation [228].  
Protein Metabolism 
 
 Insulin is a anabolic hormone that inhibits proteolysis while stimulating protein synthesis. 
Under varying conditions, insulin appears to inhibit proteasome-dependent, lysosomal and 
calpain-dependent proteolysis. However, the details and validity of insulin’s actions in these 
pathways are still unclear [225, 229]. Insulin promotes the synthesis of proteins by 
phosphorylating translation initiation factors in the cell [225]. In diabetic states, a lack of insulin 
results in protein catabolism and muscle wasting.  
 
Pathogenesis of Insulin Resistance and Type-2 Diabetes Mellitus 
Diabetes mellitus refers to a group of diseases characterized by deficiencies in insulin 
production, insulin action, or both. Categories of diabetes include type 1, Type-2, gestational, 
and cases caused by other factors such as genetics, surgery, and medications [230]. Type-1 
diabetes (T1DM) is referred to as juvenile-onset or insulin-dependent diabetes. The use of these 
other terms for T1DM have become more confusing in recent years as more children develop 
Type-2 diabetes mellitus (T2DM) and more Type-2 diabetics require insulin. In human beings, 
T1DM is a chronic, autoimmune disease resulting in T-cell destruction of insulin-producing 
pancreatic beta cells [231]. T2DM is a disease characterized by defects in insulin sensitivity and 
insulin production. In a simplified description, T2DM develops secondary to obesity-induced 
insulin resistance and subsequent exhaustion of pancreatic beta cells. Other names for T2DM 
include adult-onset and insulin-independent diabetes mellitus. According to the World Health 
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Organization, the current criteria for diagnosing T2DM is a fasting blood glucose level of 126 
mg/dl and a two-hour post glucose challenge blood level of 200 mg/dl [232].  The rate of T2DM 
has been increasing rapidly world-wide in conjunction with sky-rocketing rates of obesity. From 
1980 to 2005, the incidence of diabetes in the United States increased from 5.6 to 15.8 million 
[233]. 
Cats develop diabetes mellitus similar to T2DM in human beings [234]. The incidence of 
feline diabetes mellitus is predicted to rise as obesity rates in companion animals climb. Current 
estimates of the prevalence of feline obesity range from 30-35%, a dramatic increase from the 6-
12% prevalence in a 1974 study [235, 236]. The pathogenesis of insulin resistance and it 
progression to T2DM is a multifactorial process that has sparked much research and debate over 
the past couple of decades. Several theories have emerged to explain the development and 
progression of T2DM and the true disease pathogenesis is most likely a combination of all the 
processes described below. 
Glucotoxicity 
 
The main concept behind the glucotoxicity theory is that once primary disease of T2DM 
is established through genetic or environmental factors, hyperglycemia and increased levels of 
glucose damage beta cells and eventually lead to beta cell exhaustion and hypoinsulinemia [237]. 
The term glucotoxicity was first introduced by Unger et al. in 1985 [238]. In vitro studies using 
cultured beta cell lines show incubation in media with progressively higher concentrations of 
glucose decrease insulin gene expression, glucose-induced insulin secretion, and total insulin 
secretion [239]. However, the impact of high glucose concentrations on beta cell insulin 
production is reversible if cells are moved to a lower glucose concentration within 5-10 weeks of 
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noticeable glucotoxic effects [240]. Beta cell exhaustion occurs when cells are forced to secrete 
excessive amounts of insulin to combat hyperglycemia. Eventually the beta cells become 
“exhausted” and are unable to secrete adequate amounts of insulin in response to secretagogues. 
To determine if lower levels of insulin production were the result of glucose acting directly on 
beta cells or beta cell exhaustion, the insulin inhibitor somatostatin was incubated with beta cells. 
The group of cells cultured in high-glucose medium with somatostatin secreted substantially less 
insulin than cells without somatostatin, indicating beta cell rest; however, these cells still 
demonstrated decreased insulin gene expression, glucose-induced insulin secretion, and insulin 
content [241].   
 In vivo evidence for glucotoxicity of beta cells also exists. Studies using Zucker Diabetic 
Fatty (ZDF) rats demonstrate pharmaceuticals that lower glycemia preserve beta cell function. 
ZDF rat have mutations in the leptin receptor and are well-known models of Type-2 diabetes 
[237]. Defects in leptin receptors lead to insulin resistance and a compensatory elevation in 
insulin production. Eventually beta cells lose their ability to keep up with demand and 
hyperglycemia ensues. ZDF rats treated with the insulin sensitizer troglitazone retained normal 
beta cell structure, more GLUT-2 transporters, and better glucose-stimulated insulin release than 
untreated ZDF rats [242]. Troglitazone is a member of the PPAR-γ activating class of drugs 
called thiazolidinediones (TZD). The metabolic effects of TZD drugs involve more than just 
lowering of blood glucose, and alterations in lipid metabolism may improve beta cell function. A 
study using troglitazone found the drug also increased pancreas duodenum homeobox-1 (PDX1) 
binding in ZDF rats [243]. PDX1 is a transcription factor critical to insulin gene promoter 
activity that is disrupted by hyperglycemia [244].  
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Several lines of evidence show that excessive amounts of glucose lead to alterations in 
insulin gene expression, lower beta cell insulin content, cause inadequate glucose-induced 
insulin secretion, and induce beta cell apoptosis [244]. A primary mechanism by which excessive 
glucose is thought to cause beta cell toxicity involves production of reactive oxygen species 
(ROS). When glucose enters the cell it is metabolized by oxidative phosphorylation via the citric 
acid cycle into ATP and ROS. When excessive glucose is present in the cell, it is shifted into 
other pathways that also produce ROS. Beta cells have lower levels of antioxidant enzymes 
compared to other cell types and are vulnerable to oxidative damage [237]. In vitro and in vivo 
studies demonstrate that treatment with antioxidant compounds can prevent development of 
glucose toxicity [245-247]. Hyperglycemia also stimulates release of the inflammatory cytokine 
IL-1 from beta cells. IL-1 is thought to induce beta cell apoptosis by promoting the death 
receptor Fas [248]. 
A new term called “glucolipotoxicity” has emerged to describe effects of excess free fatty 
acids in the context of hyperglycemia on pancreatic beta cells [237]. A related discussion 
regarding the effects of free fatty acids on peripheral insulin response is found below. Excessive 
lipid levels inhibit glucose-mediated insulin secretion, reduce insulin gene expression, and result 
in cellular apoptosis [249-253]. Fatty acids have also been shown to increase basal insulin 
secretion while lowering glucose-mediated insulin secretion. Islet cells cultured in medium with 
free fatty acids have lower levels of citrate synthase activity. This eventually leads to increased 
hexokinase activity and increased glucose usage when glucose concentrations are low. Increased 
glucose consumption causes an elevation in basal insulin production [237]. 
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Lipotoxicity 
 Excess adipose tissue and insulin resistance are associated with higher concentrations of 
free fatty acids (FFA) in circulation [254]. High levels of plasma FFA lead to an increased risk of 
developing T2DM [255-257]. Acute elevations in FFA cause hyperinsulinemia by stimulating 
more insulin release from the pancreas or by reducing insulin clearance [254]; however, long-
term exposure to FFA has been shown to induce insulin resistance. Mechanisms by which FFA 
induce insulin resistance include disruption of insulin signaling, insulin-mediated glucose uptake, 
and glycogen synthesis [258, 259]. In the early 1960’s the Randle hypothesis was developed to 
explain the connection between elevated fatty acids and impaired glucose metabolism [260]. 
Randle proposed that oxidation of free fatty acids inhibits oxidation of glucose by increasing 
concentrations of glucose-6 phosphate (G-6P). High levels of G-6P allosterically inhibit 
hexokinase and prevent phosphorylation of intracellular glucose [261]. More recent studies 
demonstrating that FFA actually lower intracellular levels of G-6P have caused the Randle 
hypothesis to fall out of favor. It is now known that instead of competitively inhibiting glucose 
oxidation, FFA actually prevent glucose entry into cells by disrupting insulin signaling [261].  
Studies in people show high levels of FFA increase lipid accumulation in skeletal muscle 
cells. Fatty acid uptake into myocytes is mediated in part by the transporter proteins fatty acid 
translocase (FAT/CD36) and fatty acid binding protein (FABP). These transporters are 
abnormally redistributed to the plasma membrane in obese and diabetic states, and this 
redistribution is associated with excessive fatty acid uptake; however, the rate of oxidation does 
not increase to match the influx of FFA, and lipid accumulation results [48]. In addition to 
triacylglycerols, more reactive products of lipid metabolism such as diacylglycerol (DAG), fatty 
acyl coAs, and ceramides also amass in the myocytes.  Serine kinases such as protein kinase C 
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are activated by these lipid metabolites. The serine/threonine sites on the insulin receptor and 
insulin-receptor substrate (IRS) become phosphorylated secondary to serine kinase activation, 
and this inhibits tyrosine phosphorylation. Furthermore, the serine phosphorylation on IRS 
proteins prevents the activation of phosphatidylinositol 3-kinase (PI3K) and subsequent GLUT-4 
translocation [254]. Elevated FFA also appear to inhibit insulin signaling further downstream by 
preventing the phosphorylation of Akt/PKB [262]. Through inhibition of insulin signaling, 
intramyocellular lipid metabolites can disrupt insulin-mediated glucose transport, glycogen 
synthesis, and other insulin-mediated affects [254]. 
Amyloidosis 
 Islet amyloid polypeptide (IAPP) is a 37 amino acid polypeptide co-secreted with insulin 
from pancreatic beta cells. IAPP is also known as amylin. In early stages of T2DM, the pancreas 
attempts to keep pace with circulating glucose levels by increasing production of insulin. As a 
result, IAPP secretion is also elevated. High concentrations of IAPP can promote the formation 
of protein fibrils in which the IAPP peptides that stack upon each other in a beta pleated sheet 
structure called amyloid. Amyloid deposits are not only associated aggregations of IAPP but are 
involved with other pathological processes such as Alzheimer’s disease [263]. The formation of 
islet cell amyloid has been documented in human beings [264], macaque monkeys [265], 
raccoons [266], dogs [267], and cats [268]. Notably, mice and rats do not appear to 
spontaneously form islet amyloid deposits. Although islet amyloid has been found in dogs, it was 
associated with insulinomas and has not been shown to influence the progression of diabetes 
mellitus in this species [267].  
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 Although early in vitro studies demonstrated the presence of islet amyloid is cytotoxic to 
beta cells [269], more recent evidence suggests the majority of beta cell damage occurs during 
the formation of fibrils [270]. Specifically, soluble oligomers that precede the formation of 
amyloidogenic fibrils appear to be more cytotoxic [263]. A recent study by Meier et al. was able 
to distinguish pre-fibrillar oligomers from amyloid fibrils using oligomer-specific antibodies. 
They demonstrated that inhibition of fibril formation did not prevent apoptosis of beta cells and 
concluded oligomers were responsible for cell death [271]. Mechanisms by which amyloid 
appears to destroy cells are through membrane destabilization, the formation of non-specific 
membrane ion channels, and oxidative damage [263, 272].  
 The role of islet amyloid in the pathogenesis of T2DM has been the subject of much 
debate. Whether the formation of islet amyloid is a cause or consequence of diabetes is the 
primary question. The fact that islet amyloid only occurs naturally in species that spontaneously 
develop Type-2 diabetes (e.g. human beings and cats) suggests a pathologic role. Studies using 
transgenic mice demonstrate that insulin resistance causes increased production of IAPP and 
promotes islet amyloidosis [273, 274]. These studies also show that the amount of amyloid 
deposited is associated with a worsening of diabetes (assessed via glucose:insulin ratio) [274]. In 
reality, the answer to the question regarding the role of islet amyloid in Type-2 diabetes is 
probably that it is both a cause and a consequence. Deposition of islet amyloid is a consequence 
of increased insulin production secondary to peripheral insulin resistance. As a result, insulin 
resistance causes further damage to beta cells and ultimately contributes to decreased beta cell 
mass and hypoinsulinemia.  
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Adipokines and Inflammation 
 The connection between increased adiposity and insulin resistance is evident. With recent 
discoveries regarding endocrine functions of adipose tissue, researchers have begun to 
hypothesize a role for adipokines in the pathogenesis of insulin resistance and T2DM. In general, 
increased adiposity is associated with higher levels of adipokines and inflammatory cytokines 
that interfere with insulin action and lower levels of the insulin-sensitizing hormone adiponectin. 
The mechanisms by which individual adipokines affect insulin sensitivity have already been 
discussed; therefore, a general discussion regarding the effects of inflammatory adipokines on 
insulin action is provided. Obesity is characterized by lipid accumulation and the expansion of 
adipose cells. Enlarged adipocytes express more chemokines and proinflammatory mediators 
such as monocyte chemotactic protein-1 (MCP-1) and serum amyloid A (SAA) and have been 
shown to independently predict the development of T2DM [75, 275].  Macrophages are attracted 
by cytokines released from adipocytes and infiltrate the stromovascular regions of the adipose 
tissue [75]. As macrophages release inflammatory proteins such as TNF-α and IL-6, 
preadipocyte differentiation is impaired and adipose cells become resistant to insulin [276]. 
TNF-α is also known to suppress release of the anti-inflammatory hormone adiponectin [48]. In 
summary, as adipose tissue expands in obese individuals it becomes inflamed secondary to 
oxidative stress, free fatty acids, and cell necrosis. This results in release of inflammatory 
mediators that attract macrophages and a cycle of increased inflammation ensues. TNF-α, IL-6, 
and other cytokines interfere with insulin signaling and suppress insulin sensitizers like 
adiponectin. This ultimately contributes to development of insulin resistance [276]. 
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Feline Metabolism and Insulin Resistance 
Metabolic Adaptations in the Cat  
Mark Twain once said “If man could be crossed with the cat it would improve the man, 
but it would deteriorate the cat (Notebook, 1894).” This quote illustrates that cats are unique 
creatures with novel evolutionary adaptations. The domestic cat evolved from Asian wildcats 
(Felis silvestris lybica) near Israel and the Near East and is a strict carnivore [277]. The 
carnivorous nature of the cat has led to several metabolic idiosyncrasies. The most notable 
difference between cats and more omnivorous species like human beings and dogs is that cats 
have a much higher requirement for protein. Adult cats require about 4 grams of protein per 
kilogram of body weight compared to 2.6 in dogs and 0.8 grams in people [278, 279]. Because 
cats have evolved eating a diet plentiful in protein and low in carbohydrates, gluconeogenesis 
from amino acids is used to maintain blood glucose levels. Dietary protein is also a potent 
stimulator of insulin release in the cat. While most animals suppress gluconeogenesis during 
meals, cats actually increase hepatic glucose production during the absorptive phase to offset 
increased levels of insulin. Because cats are so dependent on protein for gluconeogensis, they 
continue metabolizing amino acids for energy even when protein malnourished. This is apparent 
by the fact that cats lack the ability to down-regulate the production of aminotransferases and 
urea cycle enzymes in response to low protein intake [280, 281].  
In addition to increased overall protein requirements, cats have increased requirements 
for individual amino acids. For example, taurine (technically a sulfonic acid rather than an amino 
acid) can be synthesized from cysteine in most species; however, cats have minimal activity of 
the enzymes required for taurine synthesis (cysteine dioxygenase and cysteine sulfinic acid 
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decarboxylase) and must obtain taurine from the diet. Also, most species use either glycine or 
taurine to conjugate bile salts into bile acids, but cats can only use taurine [282]. This causes an 
obligatory loss of taurine even in the face of deficiency. Cats also have higher requirements for 
arginine, methionine, and cysteine than other species [283].  
 While cats have metabolic adaptations designed for high dietary protein intake, they have 
also developed modifications for a low carbohydrate diet. For example, cats lack salivary and 
have low levels of pancreatic and intestinal amylase and low intestinal disaccharidase activities 
[281, 283]. Unlike more omnivorous species, cats are also unable to alter the number of intestinal 
sugar transporters to cope with changing dietary carbohydrate levels [284]. Not only are cats not 
well-adapted for digesting and absorbing large amounts of carbohydrates, they are also not 
equipped for metabolizing high glucose loads. In most species, hepatic glucokinase and 
hexokinase phosphorylate glucose to glucose-6-phosphate. Glucokinase has a low affinity for 
glucose, but is not inhibited by accumulating glucose-6-phosphate. It is the enzyme which 
handles high loads of glucose. Hexokinase has a higher affinity for glucose, but can easily 
become saturated and overwhelmed. Because cats are not expected to ingest large amounts of 
glucose at one time, they have minimal glucokinase activity in the liver [285]. Cats also have low 
concentrations of  fructokinase, needed for conversion of fructose to glycogen in the liver [283].  
 Obesity in human beings is associated with characteristic changes in lipoprotein levels. 
HDL cholesterol tends to decrease while triglyceride-containing lipoproteins tend to increase. 
Some studies suggest these characteristic cholesterol profile alterations do not occur in obese 
cats [234]. Cats lack cholesterol ester transfer protein (CETP) [286]. This protein aids in the 
transfer of cholesterol esters from HDL to lower density apo-B containing lipoproteins. It is the 
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absence of CETP in cats which is likely responsible for the high circulating HDL concentrations 
and the increased size of LDL molecules found in obese felids [234].  
Although previous studies demonstrated obese cats tend to have increased concentration 
of HDL, a recent study indicates long-term obesity in cats may lower HDL and result in higher 
percentages of small HDL3 and lower percentages of large HDL2 particles than lean cats. 
Increased concentrations of small HDL particles have been found in obese humans and are 
associated with insulin resistance [287] and cardiovascular disease[288]. As triglyceride 
concentrations rise with obesity, more TG enters HDL. The excess TG enhances hepatic 
triglyceride lipase activity and causes the formation of small dense HDL particles and accelerates 
clearance of HDL from circulation [289]. This, in turn, leads to decreased reverse cholesterol 
transport from the periphery back to the liver. Similar to humans, chronically obese cats have 
elevated plasma triglycerides and non-esterified fatty acids. Obese cats also have higher 
concentrations of VLDL than lean cats [290].  
Feline Diabetes 
Diabetes mellitus is one of the most common endocrine disorders of the domestic cat, and 
the incidence appears to be on the rise. In North America, the prevalence of feline diabetes has 
increased from 8 cases per 10,000 cats in 1970 to 124 cases per 10,000 cats in 1999 [291]. This 
increase in diabetes coincides with a dramatic rise in rate of obesity among pet cats. As stated 
earlier, the prevalence of overweight and obese cats in the United States has risen almost 30% 
over the past 25 to 30 years [292], [293].  
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Pathogenesis 
Based on islet histology and clinical manifestations, it is estimated that 80% to 95% of 
cats with diabetes mellitus have a form very similar to T2DM in humans [294]. A smaller 
percentage of cats become diabetic secondary to other diseases that damage the pancreas (e.g. 
pancreatitis, neoplasia) or induce insulin resistance (e.g. acromegaly) [295, 296]. The 
pathogenesis of T2DM in cats seems to closely resemble the human disease. In both species 
obesity is a significant factor for developing insulin resistance and diabetes mellitus. Obese cats 
have an approximate 4-fold higher risk of developing diabetes mellitus than normal weight cats 
[297]. Laboratory cats that were allowed free access to food for 10 months gained on average 
44% of their body mass and reduced their sensitivity to insulin by half. Two-thirds of the cats 
had insulin sensitivities below normal ranges [298]. Obesity is also associated with changes in 
insulin secretion in cats. While still normoglycemic, obese cats secrete more insulin and have a 
more dramatic second phase insulin response when compared to lean cats [299]. Long-term 
insulin resistance is linked with decreased insulin levels, and diabetic cats have low and 
inconsistent insulin secretion patterns [300]. 
Although obesity is major contributor to insulin resistance in cats, many obese 
individuals do not develop diabetes mellitus, and not every diabetic cat is overweight. As in 
people, other factors must be involved to convert an overweight or obese animal into a diabetic. 
In both human beings and cats, genetic predispositions for development of diabetes occurs [301, 
302]. Chronic glucose toxicity is a major contributor to pancreatic dysfunction and development 
of insulin-dependent diabetes mellitus in cats. Glucose toxicity was recently demonstrated in cats 
by a study in which glucose and lipid were infused into healthy cats for ten days. The glucose 
infusion resulted in a dramatic decline in plasma insulin levels after just two days. Beta cell mass 
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was also decreased by 50% compared to control animals. The lipid infusions had no effect on 
insulin concentrations or glucose tolerance tests [303]. Another study demonstrated that infusion 
of glucose suppresses insulin secretion and ultimately results in ketoacidosis [304]. Early stages 
of diabetes are often overlooked by pet owners, and most cats that present to veterinarians 
require insulin at the time of diagnosis. It is not uncommon for diabetes to improve dramatically 
or even resolve after weeks or months of insulin therapy without significant changes in weight 
[305]. Presumably, as hyperglycemia is brought under control the insulin suppressive effects of 
glucose on beta cells are removed. As pancreatic beta cells regain their ability to secrete adequate 
amounts of insulin, the cat no longer requires exogenous insulin.  
Lipotoxicity may also contribute to insulin resistance and diabetes in cats. In a study 
measuring skeletal muscle lipid accumulation in lean cats that became obese, lipid levels were 
significantly greater in the extramyocellular space and trended toward significance within 
myocytes [306]. In addition, lipoprotein lipase (LPL) activity is higher in skeletal muscle and 
lower in adipose tissue of obese cats when compared to lean cats [82]. Since LPL is responsible 
for transporting triglycerides from lipoproteins to the tissues, changes in its secretion pattern 
would facilitate redistribution of lipids from adipose to muscle tissue. GLUT-4 expression in 
both adipocytes and myocytes is also decreased in obese cats [307]. This reduction in insulin-
mediated transport of GLUT-4 provides indirect evidence that lipid accumulation within feline 
fat and muscle cells interferes with insulin signaling. However, Zini et al. demonstrated that 
infusion of lipids to levels seen with diabetics does not impact insulin or glucose tolerance tests 
[303]. 
Cats naturally deposit amyloid within their islet cells [268, 300, 308-311]. Although beta 
cell amyloid can be found in healthy cats as they age, levels are significantly higher in glucose-
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intolerant cats [308, 312]. Over 90% of cats with diabetes mellitus have amyloid deposits, and 
these deposits are associated with an approximately 50% reduction in beta cell mass [313]. 
Although more studies are needed to directly assess the role of islet amyloid in feline diabetes, a 
clear association exists, and the pathologic consequences are expected to be similar among 
species. 
Just as adipokines are relatively new players in the pathogenesis of T2DM in human 
beings, even less is known about these hormones in cats. Available evidence suggests feline 
adipokines behave similar to those found in other species. Therefore, it is reasonable to propose 
adipokines influence pathogenesis of feline diabetes. The details regarding feline adipokine 
research have already been described under specific hormone headings.  
Diagnosis  
 Hyperglycemia during times of stress, danger, or critical illness is an adaptive metabolic 
response and an attempt to provide rapid fuel for energy. This response is seen often in human 
critical care settings and has become an area of much clinical research and debate. During 
stressful situations adrenocorticotropic hormone (ACTH) is released from the pituitary and 
stimulates release of cortisol from the adrenal glands. In addition, epinephrine and glucagon 
levels are elevated. Together these hormones increase hepatic glucose production and induce 
insulin resistance [314]. While the stress response can lead to mild elevations in blood glucose in 
most species, cats can sometimes have dramatic rises. Glucose levels as high as 360-613 mg/dl 
have been attributed to stress hyperglycemia in cats [315]. This response can be confusing when 
attempting to diagnose diabetes in cats. Presence of glucosuria is not a clear distinction between 
diabetes and stress hyperglycemia because blood glucose over 288 mg/dl exceeds the renal 
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threshold in cats [294]. A possible contributor to development of stress hyperglycemia in healthy 
cats is the production of lactate during physical restraint and struggling. In a study by Rand et al., 
20 healthy adult cats with normal glucose tolerance tests were sprayed with water for 5 minutes 
[315]. Struggling and vocalization were the most common responses. The investigators measured 
insulin, glucagon, cortisol, epinephrine, norepinephrine, glucose, and lactate levels during and 
after the bath. Out of all these parameters, only lactate and norepinephrine correlated with 
glucose levels. It was also observed that cats which struggled the most had the highest glucose 
levels. Interestingly, the highest norepinephrine levels were recorded after glucose had peaked. 
The strong relationship between struggling, glucose, and lactate was a consistent finding, and 
lactate is able to stimulate glucose production through hepatic gluconeogenesis [315]. 
 Cats with diabetes mellitus usually present to the veterinarian with a history of weight 
loss, increased thirst (polydipsia), increase urination (polyuria), and increased appetite 
(polyphagia). Fasting blood glucose levels over 300 mg/dl combined with glucosuria are 
suggestive of diabetes. Glycosylated proteins can also be helpful for diagnosis. Fructosamines 
are formed from non-enzymatic reactions of glucose with serum proteins and represent the 
average level of glucose over a period of days to weeks. A serum fructosamine of greater than 
400 µmol/L is suggestive of diabetes [316]. Glycosylated hemoglobin (gHb) can also be 
measured and will reflect a longer time period than fructosamine. Unfortunately, neither gHb or 
fructosamine are completely diagnostic for diabetes mellitus, and most veterinarians must rely on 
a combination of clinical and laboratory findings [294].  
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Insulin Sensitivity Testing 
A variety of methods have been used for measuring insulin sensitivity in cats [317, 318]. 
Unfortunately, most of these tests are difficult to perform in a clinical setting and have been 
restricted to research use. Methods published in cats include the euglycemic hyperinsulinemic 
glucose clamp (EHC) model, the frequently sampled intravenous glucose tolerance test 
(FSIVGTT) with minimal model analysis (MMA), the modified IVGTT, and fasting levels of 
glucose and insulin [318-320].  
Euglycemic Hyperinsulinemic Glucose Clamp 
The EHC is touted as being the gold standard in insulin sensitivity testing [321]. This test 
provides a quantitative measure of beta cell and peripheral sensitivity to insulin [322]. The goal 
of the EHC is to infuse insulin at a rate high enough to mimic post-parandial insulin surges and 
suppress hepatic gluconeogenesis. While insulin is infused at a constant rate, a dextrose solution 
is also administered at a rate adequate to maintain a constant or “clamped” blood glucose level. 
This requires frequent blood sampling and mathematical adjustments [322]. Because insulin is 
being infused at a rate high enough to prevent the endogenous production of glucose, the amount 
of glucose infused should be equal to the amount of glucose that is taken up by the tissues [323]. 
The amount of dextrose needed to preserve normoglycemia will be higher in insulin-sensitive 
individuals and lower in those who are insulin resistant [322, 324].  The protocol for performing 
the EHC in cats can be found in Hoenig et al. [319].  
While the EHC is an excellent method for measuring glucose disposal and estimating the 
sensitivity of tissues to insulin, it requires a complicated, labor intensive testing protocol. 
Achieving constant glucose levels requires experience and the placement of catheters for 
infusions and blood sampling can be technically challenging. In addition, one must have access 
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to equipment sensitive enough to regulate glucose infusions (0.05ml/minute) [322]. The EHC has 
also been criticized because it measures insulin sensitivity under artificial, steady-state 
conditions. Glucose disposal is a multifactorial process that may respond differently under 
physiologic conditions. Artificial induction of hyperinsulinemia can make comparisons of EHC 
data to other methods of insulin sensitivity testing difficult [322, 323]. 
Frequently Sampled Intravenous Glucose Tolerance Testing with Minimal Model Analysis 
(FSIVGTT with MMA) 
 The minimal model is non-linear mathematical model that was developed by Bergman et 
al. in 1979 [325]. This model uses data from the FSIVGTT to indirectly measure insulin 
sensitivity. In this model glucose disposal is divided into two differential equations. One 
equation describes glucose-mediated disposal of glucose (SG) while the other represents insulin-
mediated glucose disposal (SI) [322]. Although the MMA mathematics are complex and require 
expert knowledge to fully understand, a software version of the model is available for 
researchers [326]. The FSIVGTT is technically easier to perform than the EHC. When the 
IVGTT was first developed, it required only injection of a glucose bolus followed by the 
collection of blood samples over several hours. The modified FSIVGTT involves collecting a 
baseline glucose and insulin level, injecting a bolus of glucose, and then injecting a bolus of 
insulin or tolbutamide approximately 20 minutes later. Twenty-five to thirty-two blood samples 
to measure glucose and insulin are then collected over three to five hours [322, 324].  
 The MMA can be divided into discrete phases. During the first 7-10 minutes after the 
bolus of glucose (t = 0) the pancreas is stimulated to secrete insulin, and liver gluconeogenesis 
decreases. After this initial phase, glucose disposal is mediated almost completely by glucose for 
the next ten minutes (t = 20min). This glucose-mediated glucose disposal is referred to as 
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glucose effectiveness (SG). Once insulin is injected (t = 20 min) glucose disposal becomes 
insulin-mediated. The amount of glucose removed from circulation in relation to the amount of 
insulin injected is the insulin sensitivity value (SI). One’s ability to secrete endogenous insulin 
can also be estimated by measuring the levels of insulin secreted after the glucose bolus and 
before the insulin injection. This is referred to as the acute insulin response to glucose (AIRG). 
The adequacy of insulin secretion and insulin action to dispose of glucose is called the 
disposition index (DI) and is calculated by multiplying the SI by the AIRG [324]. 
 There are several advantages and disadvantages to using the FSIVGTT with MMA. A 
major benefit of this testing method is the ability to evaluate insulin sensitivity, beta cell 
function, and effectiveness of glucose-mediated glucose disposal in a single test under dynamic 
conditions [323]. The FSIVGTT is also easier to perform than the EHC and has proven to be 
reliable in people [324]. One disadvantage to this technique is that mathematical modeling tends 
to simplify physiologic conditions. In this model, glucose dynamics are represented in a single 
compartment that tends to overestimate SG and underestimate SI. In addition, the FSIVGTT is 
still time consuming to perform, and analyzing many samples can increase cost [323]. The 
FSIVGTT with MMA has been performed repeatedly in cats [318, 327, 328] and description of 
the protocol can be found in Appleton et al. [327]. A comparison of FSIVGTT with MMA and 
the EHC in cats showed a strong correlation between the tests’ indices of insulin sensitivity (r = 
0.91, P = 0.032) [329].  
Glucose tolerance tests 
In human medicine, the oral glucose tolerance test (OGTT) is used in clinical settings to 
diagnose diabetes mellitus. In veterinary medicine, intravenous glucose tolerance tests (IVGTT) 
are more routinely performed for research studies. There are a variety of protocols for 
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administering an oral or intravenous GTT. In general, the tests consist of a baseline blood 
glucose and insulin measurement followed by administration of an oral sugar solution or 
intravenous dextrose solution. Blood glucose and insulin samples are collected repeatedly over 
the next two to three hours to measure the rate of glucose disappearance from blood [324]. 
Delayed glucose clearance in the glucose tolerance test can be due to several causes. There can 
be a dysfunction of beta cells that prevents the release of insulin, defective glucose or insulin-
mediated glucose disposal, or an adaptation in adipose tissue that spares glucose metabolism 
without compromising insulin sensitivity [322]. Although this test is simple to perform and may 
be useful for screening normal and abnormal patients, it cannot identify the specific areas of 
glucose metabolism that are compromised. 
Other simplified tests 
Given the time and expense required to perform most of the insulin-sensitivity tests 
described thus far, many simplified methods have been proposed. Unfortunately, the results of 
these tests are often unreliable, and do not always correlate well with more rigorous tests. In the 
cat, several simplified methods have been tested [318]. Most of these tests rely on calculations of 
insulin with or without glucose after either an overnight fast or a glucose challenge [330]. Two 
simplified methods of insulin sensitivity testing that correlate closely with the FSIVGTT with 
MMA in cats are the homeostasis model assessment (HOMA) and fasting glucose to insulin 
ratios (G:I) [318, 331]. HOMA is calculated by taking the product of baseline glucose and insulin 
concentrations and dividing by a constant. As a result, the HOMA value will become larger with 
lower insulin sensitivity. While this model correlates well with the MMA in obese, insulin 
resistant cats (P = 0.009, r = −0.88) this relationship is not as strong in a mixed population 
(P = 0.007, r = −0.47) [318]. The G:I in cats has not been published in a peer-reviewed format, 
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but initial results show a good correlation with MMA in healthy cats (P < .01, r = .97)[290]. This 
study involved a very small number of subjects (n = 6) and did not evaluate insulin resistant or 
diabetic cats. These simplified methods for measuring insulin sensitivity hold potential and 
hopefully will become useful research and diagnostic tools in the future. 
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CHAPTER II 
SEQUENCING OF FELINE ADIPONECTIN  
 
Introduction 
Adiponectin is an anti-inflammatory adipokine secreted almost exclusively from 
adipocytes. Adiponectin is an important insulin sensitizing agent, and overweight cats are 
susceptible to insulin resistance [129, 294]. Commercially available reagents and antibodies for 
feline research are scarce, and researchers often rely on products designed for other species. For 
example, adiponectin enzyme-linked immunoassay (ELISA) kits are commercially available for 
human beings, rodents, and dogs, but none are available for cats. Researchers must choose 
appropriate products to use in feline studies by looking for species similarities. Determining the  
protein sequence of feline adiponectin will facilitate future research by allowing scientists to 
deduce similarities in structure and binding capabilities among different species. In addition, 
having the cDNA and deduced amino acid sequence allows feline-specific products and 
antibodies to be designed. Therefore, the goal of this project was to sequence feline adiponectin 
cDNA and compare this sequence among species.  
In human beings, adiponectin is a 247 amino acid protein with a molecular weight of 
approximately 28 kda [124]. The amino acid sequence of adiponectin can be divided into four 
domains. First is a 17 amino acid leader sequence, followed by a variable 27 amino acid region. 
The third region is a collagenous domain made up of 22 Gly-X-Pro (8) and Gly-X-Y (14) repeats 
[123, 124]. Finally, the carboxyl-terminal end makes up a globular domain that is homologous to 
type VIII and type X collagens and complement factor C1q [124, 126].  
 At the initiation of this research project, less than half of the feline adiponectin cDNA 
sequence was known (Figure 2A)(GenBank accession number AJ639861). As our work drew 
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near its conclusion, the full cDNA sequence of feline adiponectin became available and was a 
near exact match for the sequence we had completed (Figure 2A)(GenBank accession number 
AB115956). Regardless, repetition of sequencing work is valuable to ensure accuracy and 
identify gene variations. This chapter will describe the steps we took to reveal the feline 
adiponectin cDNA code. 
Materials and Methods 
All PCR reactions were performed on feline visceral adipose tissue discarded during a 
routine ovariohysterectomy. The tissue was immediately placed in a liquid RNA stabilizer1 and 
frozen to -80°C. Messenger RNA was extracted using a lipid-specific extraction kit,2 and on-
column DNase digestions were performed during the extraction.3 The extraction technique was 
tested by performing reverse transcriptase (RT) real-time (Q) PCR of the ubiquitous house-
keeping gene, glyceraldehyde 3-phosphatase (GAPDH) on the extracted samples (Table 2A). 
Reverse transcription is the first step in RTQPCR. Reverse transcriptase and primers are used to 
copy mRNA sequences into cDNA. The process of PCR consists of enzymatic replication of 
DNA through cycles of heating and cooling. Primers specific for the target DNA, along with 
DNA polymerase enzymes, are used to selectively amplify the DNA sequence of interest. A 
common method used in QPCR relies on probes with fluorescent reporters attached to quenchers 
that inhibit fluorescence. As new strands of DNA are polymerized, the polymerase reaches the 
probe and separates the fluorescent reporter from the quencher, resulting in fluorescence. This 
fluorescence is detected by the thermocycler and used to detect the cycle threshold (CT) of the  
 
                                                 
1
 RNAlater, Qiagen, Valencia, CA. 
2
 RNeasy lipid tissue mini kit, Qiagen, Valencia, CA 
3
 RNase-free DNase set, Qiagen, Valencia, CA 
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Name Nucleotide Sequence 
GAPDH Forward GCTGCCCAGAACATCATCC 
GAPDH Reverse GTCAGATCCACGACGGACAC 
GAPDH Probe TCACTGGCATGGCCTTCCGT 
Race T Reverse TGAGTCATGACTCTAGCTTTT 
TTTTTTTTTTTTTTNN 
Oligo T Reverse TTTTTTTTTTTTTTTTTT 
Dog Forward 1-21 ATGCTGTTGCTRSGAGCTGTT 
Dog Forward 1-27 ATGCTGTTGCTRSGAGCTGTTCTACTG 
Cat Forward 591-614  CTCTGGCTCTGTGCTCCTCCATCT 
Pre 3’ Forward CTGATTCCAYACCWGAGGGGCTCA 
Cat Reverse 1 TGGGATTCCTGGAAACCTCTGGG 
Cat Reverse 2 TCCAATCCCACACTGAACGCTGAGC 
Table 2A: Primer Sequences 
   Nucleotide sequences of various primers used throughout the study. All 
sequences are written 5’ to 3’. 
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reaction. Sequence analysis was performed using Sequencher software.1 The cDNA sequence 
was translated into amino acids using ExPasy translate tool.2  
Sequencing the 5’ end of the cDNA sequence  
Capturing the 5’ end of the cDNA sequence was attempted by designing two forward 
primers from the 5’ end of the canine adiponectin sequence (Dog Forward 1-21, 1-27) (GenBank 
accession number AB110099) and two reverse primers from sequences we developed while 
studying the 3’ end (Cat Reverse 1 and 2)(Table 2A). All of the primers had optimal annealing 
temperatures around 61°C. Reverse-transcription (RT) was performed with each of the reverse 
primers above according to the SuperScriptTM II Reverse Transcriptase manufacturer protocol.3  
RT reactions were performed with the two reverse primers, and four combinations of PCR were 
performed using the RT products, their respective reverse primers, and one of the two Dog 
Forward primers. PCR reactions were performed using a Platinum Taq mastermix4 and the 
following PCR cycle protocol: 95°C for 1.5 minutes, 30 cycles of 50°C for 30 seconds, 72°C for 
1 min, 94°C for 1 min, followed by 50°C for 2 min, 72°C for 5 min, and holding at 4°C. Agarose 
gels (1%) containing ethidium bromide were loaded with the PCR products and run at 100mV. 
The two reactions using the Dog Forward 1-27 primer were extracted from the agarose gels 
according to manufacturer’s protocol5 and sequenced at the University of Tennessee Molecular 
Biology Resource Facility. Although primers were used that signify the start of the canine 
sequence, some base pairs were lost in the transcription process, and we did not capture the start 
codon for the feline sequence. Therefore, a forward primer (Pre 5’ Forward) was designed from 
                                                 
1
 Sequencer v. 4.2, Gene Technology Laboratory, College Station, TX 
2
 ExPasy translate tool, ExPasy Proteomics Server, http://ca.expasy.org 
3
 Superscript II Reverse Transcriptase, Invitrogen, Carlsbad, CA 
4
 Platinum Taq, Invitrogen, Carlsbad, CA 
5
 QiAquick Gel Extraction Kit, Qiagen, Valencia, CA 
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the human adiponectin sequence (Genebank accession number NM 004797) that is upstream 
from the canine sequence (Table 2A). Using a previous RT reaction with Cat reverse 1, PCR was 
performed using Pre 5’ Forward and Cat reverse 1. The product was extracted from the agarose 
gel and sequenced a the University of Tennessee Molecular Biology Resource Facility. 
Sequencing the 3’ end of the cDNA 
Reverse transcription of mRNA was performed with one of three types of primers: RACE 
T reverse primer,1 oligoT reverse primer,2 or a random primer3 (Table 2A). Random 
amplification of cDNA ends (RACE) is used to amplify unknown cDNA ends during reverse 
transcription. The RACE T reverse primer (3’ RACE) uses the poly A tail found at the 3’ end of 
mRNA to prime the sequence during reverse transcription. The oligoT reverse primer also uses 
the poly A tail for priming. Random primer sets include many different primers with the idea that 
some will be homologous to the target. Random primers were used in case the random sequence 
could bind with our unknown RNA sequence. Reverse-transcription was performed with each of 
the reverse primers above according to the SuperScriptTM II Reverse Transcriptase manufacturer 
protocol.4 The products from the RT reactions were then combined with two additional primers 
for the PCR reaction (Table 2B). The forward primer was designed based on the partial cDNA 
sequence of the cat (Cat 1-18)(GenBank accession number AJ639861): 5’- 
ACTGGAGTAACTGGGATT-3’. The reverse primer was designed from the canine adiponectin 
cDNA sequence (Dog 691-711) (GenBank accession number AB110099): 5’- 
GACTCCACCTTTACGGGCTT-3’. Q PCR was performed using OmniMix HS  
                                                 
1
 RACE T reverse primer, Sigma-Genosys, St. Louis, MO 
2
 OligoT reverse primer, Sigma-Genosys, St. Louis, MO                                                                                                                        
3
 Random Primer, Invitrogen, Carlsbad, CA 
4
 Superscript II Reverse Transcriptase, Invitrogen, Carlsbad, CA 
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ACTGGAGTAACTGGGATT-3’. The reverse primer was designed from the canine adiponectin 
cDNA sequence (Dog 691-711) (GenBank accession number AB110099): 5’- 
GACTCCACCTTTACGGGCTT-3’. Q PCR was performed using OmniMix HS lyophilized 
Master Mix and following the manufacturer’s protocol.1 The PCR cycle used for sequencing the 
5’ end was repeated. Ethidium bromide agarose gels (1%) were loaded with the PCR product of 
the combinations found in Table 2B and run at 100mV. The Race reverse primer/Race RT 
product and the Dog 691-711 reverse/random RT product had the most prominent bands. The 
PCR product was extracted from the agarose gels according to manufacturer’s protocol2 and 
sequenced at the University of Tennessee Molecular Biology Resource Facility. No discernable 
sequence was attained. A new reverse primer was designed based on a highly conserved region 
of the human cDNA sequence (Human 971-1001)(GenBank accession number AK292525)): 5’- 
GTCATGTWTRTGAARCTCCCCAG-3’. The Human 971-1001 primer and RACE T reverse 
primer underwent RT reaction with the mRNA extracted from visceral adipose using the same 
protocol as before. The RT products were then combined with four different forward primers 
(Table 2B). In addition, a RT reaction using the Cat Forward 591-614 primer was combined with 
the Human 971-1001 reverse primer and theCat Forward 591-614 forward primer. This last 
combination gave the best product when run on an agarose gel. However, no sequence was 
obtained from the product. Random primer, Oligopoly T, and Human 971-1001 were combined 
with various forward primers for RT PCR with no additional progress. DNA extracted from 
                                                 1
 Omnimix HS Lyphilized PCR Master Mix, Takara, Otsu, Shiga, Japan 
2
 QiAquick Gel Extraction Kit, Qiagen, Valencia, CA 
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Combination RT Product Forward 
Primer 
Reverse 
Primer 
A Random 
Primer 
Cat 1-18 Dog 691-711 
B RACE T 
Reverse 
Cat 1-18 Dog 691-711 
C RACE T 
Reverse 
Cat 1-18 RACE T 
Reverse 
D Poly-T Cat 1-18 Poly-T 
E RACE T  
Reverse 
Dog 1-21 RACE T  
Reverse 
F RACE T  
Reverse 
Dog 1-27 RACE T  
Reverse 
G RACE T  
Reverse 
Cat 591-614 RACE T  
Reverse 
H RACE T  
Reverse 
Pre 3’ Forward RACE T  
Reverse 
I Human 971-
1001 
Dog 1-21 Human 971-
1001 
J Human 971-
1001 
Dog 1-27 Human 971-
1001 
K Human 971-
1001 
Cat 591-614 Human 971-
1001 
L Human 971-
1001 
Pre 3’ Forward Human 971-
1001 
M Cat 591-614 Cat 591-614 Human 971-
1001 
Combinations of primers, probes, and RT product used to capture the 5’ 
end of feline adiponectin cDNA. None of the combinations provided 
discernable sequences. 
Table 2B: Primer and RT Product Combinations 
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feline serum was also subjected to PCR using either Oligopoly T or Human 971-1001 and the 
forward primer Cat Forward 591-614. No product was visible on agarose gels. 
Results 
701 out of 735 base pairs were sequenced (Figure 2A). The 5’ end of the cDNA sequence 
was completed and only the last 20 base pairs of the 3’end were unresolved. Our sequence 
differed from the complete sequence by 7 base pairs and from the partial sequence by 4 base 
pairs. Most of these differences were silent and did not alter the amino acid translation. The 
deduced amino acid sequence was 233 AA. There were two differing amino acids (position 5 and 
148)(Figure 2B). The substitution of glycine for arginine at position 5 is within the leader 
sequence of the adiponectin and is not expected to affect the final protein structure. The glycine 
found at position 148 of our sequence is in agreement with other species (dog, rabbit, mouse, 
human). Our cDNA sequence was highly homologous to canine (91%), human (87%), and 
mouse (84%) adiponectin cDNA (Genbank numbers NM_001006644, EU420013, EF601160). 
The translated amino acid sequence (Figure 2B and 2C) is similar to canine (91%), mouse 
(88%), and human (85%) adiponectin (Genbank numbers NP_001006645, AAZ86518, 
NP_004788, respectively). 
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Figure 2B: Translated Amino Acid Sequence of Feline Adiponectin  
Figure 2B: Translated amino acid sequence of our cDNA sequence compared to the 
other published feline sequence (blue – our sequence, black - GenBank accession 
number AB115956). There are two differing amino acids. The substitution of glycine 
for arginine at position 5 involves the leader sequence. The glycine found at position 
148 of our sequence is in agreement with other species (dog, rabbit, mouse, human). 
 
 
1     MLLLGAVLLLLVLPIRGQDSETEGPGVVVPLPKGACTGWMAGIPGHPGHNGTPGRDGRDG  60 
      |||| ||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
1     MLLLRAVLLLLVLPIRGQDSETEGPGVVVPLPKGACTGWMAGIPGHPGHNGTPGRDGRDG  60 
 
61    TPGEKGEKGDPGLVGPKGDTGETGVTGIEGPRGFPGIPGRKGEPGESAYVYRSAFSVGLE  120 
      |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
61    TPGEKGEKGDPGLVGPKGDTGETGVTGIEGPRGFPGIPGRKGEPGESAYVYRSAFSVGLE  120 
 
121   SRVTVPNVPIRFTKIFYNQQNHYDVTTGKFHCNIPGLYYFSYHITVYLKDVKVSLYKRDK  180 
      ||||||||||||||||||||||||||| |||||||||||||||||||||||||||||||| 
121   SRVTVPNVPIRFTKIFYNQQNHYDVTTRKFHCNIPGLYYFSYHITVYLKDVKVSLYKRDK  180 
 
181   AMLFTYDQYQEKNVDQASGSVLLHLETGDEVWLQVYGDGDYNGLYADNVNDST  233 
      ||||||||||||||||||||||||||||||||||||||||||||||||||||| 
181   AMLFTYDQYQEKNVDQASGSVLLHLETGDEVWLQVYGDGDYNGLYADNVNDST  233 
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Figure 2C: Translated Amino Acid Sequence of Feline , Canine, 
Mouse, and Human Adiponectin  
Figure 2C: Translated amino acid sequence of our cDNA sequence compared canine 
(NM_001006644), mouse (EF601160), and human (EU420013) sequences. Red stars 
indicate areas where two or more amino acids differ. Blue stars represent single amino 
acid differences, and green stars indicate amino acids where the cat differs from all 
other species listed. 
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Figure 2C Continued: Translated Amino Acid Sequence of Feline, 
Canine, Mouse, and Human Adiponectin  
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Discussion 
Sequencing the feline cDNA for adiponectin is an important first step for studying this 
hormone in cats. Our project sequenced 97% of the feline adiponectin cDNA and had <1% 
variation from the completed cDNA. This small variation may be the result of different peak 
interpretations of sequencing results or may reflect normal variation among individual cats. This 
project also demonstrated that feline adiponectin is similar in gene and amino acid structure to 
other species. The results from this study will aid in the creation or selection of antibodies to 
detect feline adiponectin and will be critical for developing real time PCR applications.  
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CHAPTER III 
ADIPONECTIN mRNA EXPRESSION IN THE CAT 
 
Introduction 
The metabolic role of adipose tissue is a rapidly expanding area of research. Discovery of 
cell-signaling proteins secreted by adipocytes, termed adipokines, dispelled the belief that fat is a 
passive tissue functioning solely for energy storage and insulation. Adiponectin is the most 
abundantly secreted adipokine with serum concentrations in the µg/ml range, which is three 
orders of magnitude higher than leptin [129]. One of the most intriguing aspects of adiponectin is 
its paradoxical decline with increases in body fat mass. Adiponectin is closely associated with 
insulin sensitivity and has beneficial cardiovascular effects [181, 332-336]. Adiponectin’s role in 
metabolism and diabetes mellitus is of interest in feline medicine because cats are susceptible to 
developing insulin resistance and Type-2 diabetes in response to weight gain [235, 298]. Only 
one study has evaluated the mRNA expression of feline adiponectin, and it was limited in the 
scope of tissues examined [72, 212]. 
Although adiponectin is secreted predominately from adipocytes in the species studied, 
small amounts have been found in preadipocytes from bone marrow [337], cultured cardiac 
myocytes [136], and portal endothelial cells [137]. In dogs, adiponectin mRNA expression has 
only been detected in adipose tissue [338].  In a single study of cats, adiponectin expression was 
examined in adipose tissue and skeletal muscle [72, 212]. Visceral adipose appeared to have 
higher tissue expression of adiponectin than subcutaneous adipose tissue. This is in contrast to 
studies in human beings where subcutaneous adipose tissue secretes 25-60% more adiponectin 
than visceral adipose [157, 339-341]. Findings in human beings coincide with research linking 
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visceral adiposity to lower levels of circulating adiponectin and higher risks of cardiovascular 
disease and T2DM [160, 342]. 
To fully understand adiponectin’s impact on feline metabolism, it is important to 
determine the tissues from which it is derived. It is not uncommon for hormones and adipokines 
to have dramatic species differences in their secretion patterns. For example, resistin is a 
hormone secreted almost exclusively from adipose tissue in rodents, but it is predominately 
found in bone and lung tissues of human beings [92, 95]. The goal of this study was to quantify 
adiponectin’s expression in various tissues and determine the primary areas of adiponectin 
production. By knowing which tissues exert the greatest influence on circulating adiponectin, we 
may better understand which areas of the body impact insulin sensitivity. As a result, new 
preventive and therapeutic measures may be implemented to increase circulating adiponectin 
levels and subsequently improve insulin sensitivity in cats. 
Materials and Methods 
Sample Collection 
Three feline cadavers were obtained from a local humane society. Cats were euthanized 
for reasons unrelated to the study and samples were collected immediately after expiration. The 
cats’ physical parameters are described in Table 3A. The following tissues were harvested using 
sterilized instruments treated to remove DNA contamination:1 inguinal subcutaneous adipose, 
visceral mesenteric adipose, liver from the left lateral lobe, skeletal muscle from the 
gastrocnemius, left ventricular cardiac muscle, aorta, stomach fundus, duodenum, pancreas, 
thyroid gland, adrenal gland (cortex and medulla), and renal cortex. Care was taken 
                                                 
1
 DNA Away, Molecular Bioproducts, San Diego, CA 
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Sex Age Breed Body Weight 
Body 
Condition 
Score 
Cat A Female <3 
years 
Domestic 
Short 
Hair 
3.14 kg 4/9 
Cat B 
Male 1-2 
years 
Domestic 
Short 
Hair 
4.45 kg 5/9 
Cat C Male 1-2 
years 
Domestic 
Short 
Hair 
3.96 kg 5/9 
Table 3A: Description of Sample Cats 
Description of cats from which tissue samples were collected. 
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to remove surrounding fat from tissues, and new instruments were used for the collection of each 
sample. Tissues were immediately placed in a RNA preservative1 and frozen to -80°C.  
RNA extraction and PCR  
Messenger RNA was extracted from adipose tissue using a lipid-specific extraction kit to 
improve RNA yield.2 All other tissues were extracted using a standard mRNA extraction kit.3 
On-column DNase digestions were performed during the extraction,4 and samples were stored at 
-80°C. An additional DNase treatment was performed to remove residual DNA before samples 
were reverse transcribed.5 
Reverse-transcription (RT) was performed on each sample according to the SuperScriptTM 
II Reverse Transcriptase manufacturer protocol.6 The reverse priming and quantitative, real-time 
(Q) PCR were performed with the following primers and FAM-labeled probe designed for this 
study.7 They included forward primer (18 µM): 184 – CCGGGTGAAAAGGGTGAG – 201, 
probe (5µM): 222 – AACAAGACCTGGATCTCCT – 204, and reverse primer (18 µM): 245 – 
TCACCAGTGTCACCCTTAGGA – 225. cDNA sequence locations correspond to GenBank 
accession number AB115956. FAM-labeled probes are more specific than cyber green markers 
used previously for feline adiponectin PCR, and the specificity of the primers and probe were 
confirmed through DNA sequencing of the PCR product [212]. For Q-PCR, cDNA (2µl) was 
combined with the primer and probe mixture (1µl),8 Taq polymerase (2x concentration, 10µl),1 
                                                 
1
 RNAlater, Qiagen, Valencia, CA 
2
 RNeasy lipid tissue mini kit, Qiagen, Valencia, CA 
3
 RNeasy minikit, Qiagen, Valencia, CA  
4
 RNase-free DNase set, Qiagen, Valencia, CA 
5
 TURBO DNA-free, Ambion, Austin, TX 
6
 Superscript II Reverse Transcriptase, Invitrogen, Carlsbad, CA 
7
 Taqman custom gene expression assay, Applied Biosystems, Foster City, CA 
8
 Taqman custom gene expression assay, Applied Biosystems, Foster City, CA 
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and water (7µl). The total reaction volume was 20 µl. The amplification profile consisted of 2 
min at 50ºC and 10 min at 95ºC, followed by 40 cycles of 95ºC for 15 sec and 60ºC for 1 min. 
The ubiquitously expressed housekeeping gene, glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) was used as a control to assess the relative quantity of mRNAextracted from different 
tissues. RT and Q-PCR using the same protocol as above with GAPDH specific primers and 
probes were performed for each sample. Extracted mRNA from tissue samples that had not 
undergone an RT reaction was also subjected to Q-PCR using the adiponectin primers to assess 
potential DNA contamination in the samples.  
Statistical methods 
To confirm linearity of each Q-PCR assay performed, a standard curve of adiponectin 
DNA using ten fold dilutions ranging from 1x101 to 1x105 was measured. To obtain a consistent 
number of adiponectin DNA copies, a plasmid with an adiponectin gene insert was constructed.2 
Standard curve equations were developed using SPSS v. 15.3   
Results 
The efficiency of RNA tissue extraction using GAPDH showed all tissues had Q-PCR 
CT values well below comparable adiponectin levels. Mean GAPDH and adiponectin CT values 
for all tissues were 14.9 (±3.8) and 25.4 (±6.3), respectively (Figure 3A). The amount of DNA 
remaining in tissues was measured using untranscribed mRNA in the Q-PCR reaction. Cats A 
and C had no detectable DNA contamination. Cat B had small amounts of DNA detected in the  
 
                                                                                                                                                             
1
 Taqman Universal PCR master mix, Applied Biosystems, Foster City, CA 
2
 TA cloning kit (pCR 2.1), Invitrogen, Carlsbad, CA 
3
 SPSS v. 15, SPSS Inc., Chicago, IL 
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Figure 3A: Real Time PCR Values for Adiponectin mRNA Expression 
Figure 3A: Bar graph of the cycle threshold (Ct) values for each tissue examined in 
three cats. 
Real Time PCR Values for Adiponectin
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pancreas and adrenal gland. Adiponectin levels measured in these two tissues were negligible 
compared to adipose tissue; therefore, the DNA contamination did not affect overall results.  
To compare adiponectin expression of various tissues, the number of DNA copies of the 
adiponectin-inserted plasmid was calculated (9.89x1019/ml). The standard curves created from 
the diluted plasmid DNA fit a logarithmic curve (R2>.97) and the CT values from the various 
tissues were then fit to the curves. Once the PCR values were standardized to the curve, the 
relative number of DNA copies of each tissue was compared to visceral adipose tissue (Table 
3B). Expression of adiponectin was highest in visceral adipose tissue in cats A and C and equal 
to subcutaneous adipose in cat B. Both types of adipose tissue had high levels of adiponectin 
expression compared to other tissue types. With the exception of subcutaneous adipose, adrenal 
tissue, and aorta, adiponectin expression was less than 1% of visceral adipose in all samples. 
Expression of adiponectin in all tissues was less than 3% of adipose tissue expression.  
Discussion 
 Based on a prevalence rate of 0.0124%, there are over one hundred thousand diabetic cats 
in the United States [291, 343]. This number is expected to rise as the rate of feline obesity 
increases [235, 292]. Therefore, researchers and veterinarians need to look for new ways to 
combat and treat feline obesity and diabetes. Adiponectin is an attractive target for early diabetic 
screening and new drug therapies, and understanding its physiology is critical for therapeutic 
applications in felids. The twelve types of tissue sampled for this study were chosen either for 
their involvement in carbohydrate and lipid metabolism or for their known endocrine functions. 
Although adipose and skeletal muscle had been previously evaluated in the cat, many other 
tissues hold the potential to secrete adiponectin. As stated previously, small amounts of 
adiponectin expression have been detected in several human and rodent tissue types, and 
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Tissue Type Cat A Cat B Cat C Mean 
Renal cortex <0.1 <0.1 <0.1 <0.1 
Skeletal muscle 0.3 <0.1 <0.1 0.1 
Liver <0.1 <0.1 <0.1 <0.1 
Thyroid gland <0.1 0.1 1.1 0.4 
Aorta <0.1 0.7 2.4 1.0 
Fundus 0.2 <0.1 0.6 0.3 
Cardiac muscle <0.1 <0.1 0.3 0.1 
Adrenal gland <0.1 0.1 6.5 2.2 
Duodenum <0.1 <0.1 0.1 <0.1 
Pancreas <0.1 0.3 0.3 0.2 
Subcutaneous 
adipose 87.0 100 75 87.3 
Visceral adipose 100.0 100.0 100 100 
Table 3B: The expression of adiponectin mRNA relative to visceral adipose. 
Note the high levels of expression in the aortic and adrenal tissue from Cat C. 
This is most likely due to contamination with adipocytes given the small 
amounts detected in the other two cats.  
 
Table 3B: Relative Amounts of Adiponectin mRNA Expression 
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adipokines can have dramatic species differences in their secretion patterns [92, 95, 136, 137, 
337, 344]. Our results show that adiponectin is secreted almost exclusively from adipose tissue in 
the cat. In comparison to visceral adipose, most other tissues had expression values of less than 
one percent. The aorta and adrenal gland tissue from cat C had expression levels of 2.4% and 
6.5%, respectively. Cats A and B had levels below 1% for these tissues. Despite efforts to 
minimize contamination of samples by adipose tissue, the adrenal and aorta samples from cat C 
may have been contaminated by surrounding fat, and this would falsely increase adiponectin 
mRNA levels. Although we cannot rule out the possibility that aortic and adrenal tissues secrete 
small amounts of adiponectin, the amounts of adiponectin mRNA detected in the non-fat samples 
are considered clinically and biologically irrelevant and are probably the result of adipocyte 
contamination within the tissues. 
 Identifying the tissues that secrete adiponectin in cats is an important first step in 
characterizing this hormone. This study demonstrates cats are similar to other species in that 
adiponectin is secreted almost exclusively from adipose tissue. However, cats differ from other 
species in their relative expression of adiponectin from visceral and subcutaneous adipose. We 
found visceral adipose samples express approximately 12% more adiponectin mRNA than 
subcutaneous samples. The finding that visceral adipose expresses more adiponectin mRNA than 
subcutaneous adipose is in agreement with another study in cats in which visceral adipose 
expressed 50% more adiponectin than subcutaneous adipose [212]. This is an intriguing finding 
because humans secrete 25-60% less adiponectin from visceral fat [157, 339, 341]. Since humans 
secrete more adiponectin from subcutaneous adipose, a person with more visceral fat will have 
less adiponectin than a person with the same body fat content who has more fat distributed 
subcutaneously. This is a possible mechanism for the deleterious cardiovascular and metabolic 
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affects  associated with visceral adiposity in people [19]. The opposite pattern may be seen in 
cats. A cat with larger deposits of visceral fat would be expected to have more circulating 
adiponectin than a cat of the same body fat mass with more subcutaneous adipose tissue. Perhaps 
visceral adiposity may not be as detrimental to cats as it is in humans, and maybe subcutaneous 
adipose depots may contribute more to the development of insulin resistance and diabetes in cats.  
The results of this study are intriguing and provide the opportunity for many additional 
projects. It would be interesting to compare adiponectin expression patterns in adipose tissue of 
cats with different genders, ages, breed, and body condition scores.  For example, could 
adiponectin expression hold the key to understanding the increased incidence of diabetes mellitus 
in male cats [291]. From the results of this study, we know adiponectin is truly an adipokine 
secreted only from fat tissue in cats, and future research efforts can concentrate on how adiposity 
patterns influence adiponectin and if this relationship impacts insulin sensitivity. 
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CHAPTER IV 
VALIDATION OF TECHNIQUES FOR MEASURING FELINE 
ADIPONECTIN AND ITS MULTIMERIC FORMS 
 
Introduction 
In the past fifteen years, immense research efforts in human medicine have focused on 
obesity as a disease and the role of adipose tissue in the pathology of obesity. We now know 
adipose tissue is an endocrine organ, and nearly 100 proteins are secreted from adipocytes [1].  
Proteins, hormones, and cytokines derived from adipose tissue are called adipokines. In humans 
and mice, adiponectin is the most abundant adipokine. It circulates in multimeric forms 
categorized as low molecular weight (LMW) trimers (~70-90kDa), medium molecular weight 
(MMW) complexes (~120-180kDa), or high molecular weight (HMW) complexes made up of 12 
-18 subunits (>220kDa) [123]. Studies in both mice and humans demonstrate that 
HMW/(HMW+LMW), termed high molecular weight ratio (HMWR), is a better predictor of 
insulin resistance than total adiponectin levels [132, 335].  
Cats are susceptible to developing insulin resistance and Type-2 diabetes with obesity.  
Obese cats have an almost 4 fold higher risk of developing diabetes than normal weight cats. 
Few researchers have evaluated adiponectin in companion animal species and only two 
publications describing feline adiponectin are currently available [72, 212]. Because the 
incidence of feline obesity is rapidly growing [235] and cats are susceptible to the development 
of Type-2 diabetes with weight gain, a reliable method for measuring total adiponectin and its 
multimeric forms are needed to initiate research of feline adiponectin. Therefore, the purpose of 
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this study was to validate a commercial Enzyme-linked Immunosorbent assay (ELISA)1 kit for 
use in cats and develop a method for measuring the HMWR of feline adiponectin.  
Materials and Methods 
Total adiponectin  
Frozen (-80°C) feline serum samples submitted to the University of Tennessee Clinical 
Endocrinology laboratory for thyroid testing were pooled to form three samples representing 
high (H), medium (M), and low (L) concentrations of adiponectin. Individual samples were 
tested using the adiponectin ELISA1 before being placed into a specific category. Ten to fifteen 
specimens from individual cats were used in each pooled sample. The optimal serum dilution 
was determined by testing ratios of 1:100, 1:250, 1:500, 1:1000, 1:2000, and 1:4000 of serum to 
sample diluent provided with the kit and comparing the values to the assay’s standard curve 
(Figure 4A). The standard curve was derived using known quantities of mouse adiponectin 
provided with the kit. Curve results fit best to an exponential model and the equations derived 
from this model were used for calculating relative adiponectin levels in the feline samples tested. 
The 1:1000 and 1:500 dilutions fell within the linear range of the standard curve while also being 
in the mid-range of assay detectability. The 1:1000 dilutions were used for all samples unless 
otherwise noted. Intra-assay and inter-assay coefficients of variation were assessed using six 
replicates of the H, M, and L samples in three separate assays and three replicates of H, M, and L 
samples in five separate assays, respectively. Linearity of the assay was determined by diluting 
H, M, and L to 1:500, 1:1000, 1:2000, and 1:4000 over two  
                                                 
1
 Murine adiponectin ELISA kit, B-Bridge International, Sunnyview, CA  
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Figure 4A: Comparision of Serial Dilutions to Standard Curve 
Figure 4A: To determine the optimal sample dilution, feline serum samples were diluted 
1:250 to 1:4000 and fit to the standard curve. Both 1:1000 and 1:500 fit the linear portion of 
the standard curve. The 1:125 dilution was beyond the standard curve. 
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separate assays. Assay recovery was measured by spiking two feline serum samples (M and L) 
with 4 ng/ml, 2ng/ml, 1ng/ml, or 0.5ng/ml of mouse adiponectin over three separate assays. 
Mouse adiponectin provided with the ELISA kit was used for spiking since purified feline 
adiponectin is not readily available.  
Although commercial feline adiponectin and adiponectin antibody are not currently 
available, we used a series of size separation steps to enrich feline adiponectin for testing with 
the ELISA. 500µl of feline serum underwent size exclusion gel chromatography (see below).1 50 
protein fractions were collected using an automated fraction collector.c Bicinchoninic acid 
(BCA) protein analysis was used to determine which fractions contained serum proteins (Figure 
4B).2 These fractions were then run on a non-reducing 4-15% gradient gel with SDS-PAGE 
electrophoresis to separate by size.3 The gel was then stained with a Coomassie blue stain4 to 
determine which protein fractions contained molecules in the size range of HMW adiponectin 
(>200 kda) (Figure 4C). The large protein fractions were pooled and subjected to electrophoretic 
separation using a reducing 10% preparative SDS-PAGE gel.5 Reducing buffer was used to 
break secondary and disulfide-linked tertiary structures. The monomeric (30kDa) form of 
adiponectin will remain intact with a reducing buffer. Most of the larger adiponectin complexes 
should break down to the monomeric form. Staining with Coomassie blue showed that some of 
the protein segments that had previously been >200 kda were reduced to a band of about 30 kDa. 
 
                                                 
1
 Ultrogel AcA 34, Sigma-Aldrich, St. Louis, MO 
2
 BCA protein assay, ThermoFisher Scientific, Pittsburgh, PA 
3
 Ready Gel Tris-HCl Gel, 4–15% linear gradient, Bio Rad, Hercules, CA 
4
 Gel Code Blue stain, ThermoFisher Scientific, Pittsburgh, PA 
5
 Ready Gel Tris-HCl Gel, 10%, Bio Rad, Hercules, CA 
 
 85 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4B: Sample BCA Protein Assay 
Figure 4B: Sample BCA protein assay used to test which fractions contain 
protein following gel chromatography. This picture shows 65 fractions 
tested with the last two wells containing negative controls. Color change to 
purple indicates the presence of protein. In this example, fractions 5-55 
contain detectable levels of protein. Following the BCA assay, the 
transition of samples greater than and less than 200 kDa was detected by 
using gel electrophoresis (Figure 4C). 
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Figure 4C: Gel Electrophoresis of Chromatography Fractions 
Figure 4C: Sample gel from a non-reducing 4-15% gradient SDS-PAGE in which 
fractions from the gel chromatography were loaded. This example coincides with the 
BCA assay in Figure 1. Since protein was not detectable until sample 5, the transition 
of proteins from greater than to less than 200kDa was expected to occur around 
sample number 20. Therefore, samples 16-26 were tested in lanes 2-12. Lane one 
contains a protein marker. Protein bands transition from predominately >200kDa to 
mostly <200kDa around sample 21. 
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This denaturing of a large protein to its 30kDa monomeric should effectively separate 
adiponectin from most other proteins of similar size. The 30kDa band was cut from the gel and 
proteins within this band were eluted using a Centrilutor microeluter.1 The proteins were eluted 
into 10kDa NMWCO membranes2 using degassed 0.025M tris, 0.192 M glycine buffer at a pH of 
8.4 and 200V constant voltage. The retained sample was then concentrated and placed into 
phosphate-buffered saline. This extracted sample was used to confirm the murine ELISA kit’s 
ability to detect feline adiponectin. The concentration of the sample was 0.5 µg/ml. The size 
reduction of proteins from >200kDa to ~30kDa was used to eliminate most proteins other than 
adiponectin. However, we can not rule out the possibility that other proteins remained in the 
sample. 
High Molecular Weight Ratio 
Size exclusion gel chromatography was used to separate feline serum into protein 
fractions > and < 200kda. The column was packed with composite polyacrylamide-agarose beads 
with a fractionation range of 20-350 kDa.3 The suspension was rinsed and soaked in PBS buffer 
before packing the column. 250µl of serum from each sample was treated with 1µl of the 
protease inhibitor, aprotinin,4 and loaded onto the column. The flow rate was 0.8 mls/min and 1.5 
ml fractions were collected. The first 50 mls of column flow, which did not contain protein, was 
discarded for each sample. The presence of protein was detected in the collected fractions using 
bicinchoninic acid (BCA) protein analysis (Figure 4B).5  
                                                 
1
 Centrilutor microelutor, Millipore, Billerica, MA 
2
 Biomax-10 membrane, Millipore, Billerica, MA 
3
 Ultrogel AcA 34, Sigma-Aldrich, St. Louis, MO 
4
 Aprotinin, Fisher Bioreagents, Pittsburgh, PA 
5
 BCA protein assay, ThermoFisher Scientific, Pittsburgh, PA 
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To determine which protein fractions were >200 kda (HMW) and <200kda (LMW), 
samples were run on a non-reducing 4-15% gradient SDS-PAGE gel. The gel was then stained 
with Coomassie blue stain (Figure 4C). Separation of column fractions by size was also 
confirmed using feline immunoglobulin G (IgG) and M (IgM) assays.1,2 IgG is approximately 
150kda, and IgM is about 900kda. The samples suspected of containing proteins <200kda 
contained substantial levels IgG and little IgM, while the reverse was true for samples >200kda. 
The first fifteen protein samples collected from the column consistently contained the large 
protein fractions. Once serum proteins were separated into >200kda and <200kda size, the 
amount of adiponectin present in each group was tested in duplicate using the ELISA method 
detailed previously. Because serum samples become diluted when exposed to gel 
chromatography, a dilution factor of 1:10 was used with the ELISA instead of the customary 
1:1000. The intra and interassay variability of the gel chromatography combined with the ELISA 
were tested by running two different serum samples through the chromatography column three 
different times. These six samples were tested in the same manner above with BCA protein 
assays to determine which samples contained protein and with SDS page gel electrophoresis to 
determine where protein sizes change. The samples were then tested in triplicate with the ELISA. 
The ratios of HMW adiponectin and LMW adiponectin were determined using the formulas: 
HMW/(HMW+LMW) and LMW/(HMW+LMW), respectively [132, 133].  
                                                 
1
 Cat IgG ELISA, Bethyl laboratories, Montgomery, TX 
2
 Cat IgM ELISA, Bethyl laboratories, Montgomery, TX 
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Statistical Analysis 
Coefficients of variation and standard deviations were calculated using SPSS v.15.0.1 
Exponential standard curve models were derived using software provided with the microplate 
reader.2 R-square values for linearity were determined using Microsoft Excel 2000.3 
Results 
Intra-assay and inter-assay coefficients of variation (CV) for the ELISA measuring total 
adiponectin were <4% and <7%, respectively. Serial dilutions of 1:4000 thru 1:1000 are highly 
linear with a mean R2=0.97. When the 1:500 dilution is included, a logarithmic scale was more 
appropriate (mean R2=0.90)(Figure 4D). On average, 91 ±11% of mouse adiponectin spiked into 
feline samples was recovered. According to the kit’s manufacturer, the minimum detectability of 
the assay is 15.6 pg/ml and linear range is 0.25 to 8 ng/ml of adiponectin. The intra and inter 
assay CV for the HMWR assay were 6% and 5%, respectively. 
Discussion 
The ELISA kit used for the study was chosen because it has been successfully used by 
another investigators [72, 345]. Although a canine kit was available and the amino acid sequence 
of feline adiponectin is closer to dogs (91%) than mice (88%), no reactivity was found using the 
canine kit. Precision in a diagnostic test is critical for accurate results. The intra- and inter-assay 
variation of the ELISA in this study is minimal at <4% and <7%, respectively. These results are 
similar to those published by the kit’s manufacturer (intra-assay CV 2.5-5.8%, inter-assay CV 
4.6-7.2%). The spike and recovery procedure tests the assay’s ability to accurately measure a 
known quantity of adiponectin over various concentrations. On average, a high amount of mouse  
                                                 
1
 Statistical software v. 15, SPSS Inc, Chicago, IL 
2
 KCjunior, Bio-Tek Instruments, 2000, Winooski, VT 
3
 Excel spreadsheet software, Microsoft Corporation, Redmond, WA 
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Figure 4D: Assay Linearity for Serum Adiponectin 
Figure 4D: Graphs demonstrating the linearity of feline serum sample diluted 
and tested with the adiponectin ELISA. The samples represent low (L), 
medium (M), and high (H) concentrations of adiponectin. The dilution factors 
were 1:4000 (log value 0.00025), 1:2000 (log value 0.0005), 1:1000 (log value 
0.001), and 1:500 (log value 0.05) and data points corresponding to these 
dilutions are read from left to right. Dilutions 1:4000 thru 1:1000 are highly 
linear with a mean R2=0.97. When the 1:500 dilution is included, a logarithmic 
scale is more appropriate (mean R2=0.90). 
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adiponectin spiked into feline samples was recovered (91%). The linearity of diluted samples 
was satisfactory over the range of 1:4000 to 1:1000, but inclusion of the 1:500 dilution resulted 
in a logarithmic pattern. This suggests the kit is more linear at higher dilutions and supports the 
choice to use a dilution factor of 1:1000 rather than 1:500 for measuring feline samples.    
Although the line slopes varied among samples, some variability is expected with a 
biological assay, and the results suggest the same protein is being measured in the samples and 
the standard curve. Western blot analysis was attempted to confirm the binding of the ELISA 
kit’s antibody (polyclonal rabbit anti-mouse) to feline adiponectin. Unfortunately the antibody 
failed to bind any of the species tested (mouse, rabbit, cat, bear, and horse). It is likely the 
antibody from the ELISA kit binds to a specific epitope of the adiponectin protein that is 
damaged or affected by conformational changes induced by the Western blot technique.  Size 
exclusion was then used create an enriched sample of adiponectin from feline serum for testing 
with the ELISA. Using gel chromatography, we separated out large serum proteins (>200kDa) 
from small proteins. Using a denaturing buffer, we then broke the bonds holding adiponectin 
multimers together and created a band of 30kDa proteins. Few proteins denature from a large 
molecular weight to 30kDa, and it is likely that adiponectin made up a large portion of the 
protein left in the 30kDa band. The concentration of protein in the 30kDa band was low after 
purification, but the adiponectin ELISA was still able to detect significant amounts of protein. 
We considered amino acid sequencing of the enriched adiponectin sample, but the concentration 
was too low for testing. 
The ability to measure HMW adiponectin in cats is critical for determining adiponectin’s 
role in feline metabolism. Several techniques have been used to measure HMWR in humans and 
Western blotting is one of the most popular. We attempted Western blotting for our project, but a 
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suitable antibody for feline adiponectin could not be found. Large proteins can be difficult to 
transfer in Western blots, and HMW forms of feline adiponectin could not be resolved with the 
antibodies tested. Since we had an ELISA that would accurately measure feline adiponectin, we 
decided to separate adiponectin into it’s multimeric forms with size exclusion gel 
chromatography and use the ELISA to determine the ratio of HMW to LMW adiponectin. The 
repeatability of this method was excellent with 6% intra and 5% inter assay coefficients of 
variation.  
  In conclusion, this study validates the use of a readily available ELISA kit to measure 
feline adiponectin and provides a reliable method for measuring the HMWR of adiponectin. 
These are two essential tools for future research regarding adiponectin in cats and may aid in 
earlier detection and treatment of feline diabetes mellitus. 
 
 93 
CHAPTER V 
THE INFLUENCE OF GENDER AND SEXUAL ALTERATION STATUS 
ON ADIPONECTIN AND ITS MULTIMERIC FORMS IN DOMESTIC 
CATS 
 
Introduction 
Adiponectin is a metabolically important hormone secreted almost exclusively from 
adipocytes. Although adiponectin is produced by adipose tissue, its plasma concentrations 
decline as body fat mass rises. Adiponectin is closely associated with insulin sensitivity, 
independent of body fat mass, and is an early marker for individuals at risk for T2DM [183-185, 
346]. Prospective and longitudinal studies in humans also demonstrate lower adiponectin levels 
are closely associated with insulin resistance and the future development of diabetes [185-187]. 
Adiponectin’s role in metabolism and diabetes mellitus is of interest in feline medicine because 
cats are susceptible to developing Type-2 diabetes with weight gain [297, 298]. The prevalence 
of overweight and obese cats in the United States has risen almost 30% over the past 25 to 30 
years [292, 293]. This dramatic increase in obesity coincides with a rise in the rate of diabetes 
mellitus among pet cats. In North America, the prevalence of feline diabetes has increased from 
8 cases per 10,000 cats in 1970 to 124 cases per 10,000 cats in 1999 [291]. Therefore, it is 
important for researchers and veterinarians to find new ways to combat and treat feline obesity 
and diabetes. Studies evaluating adipose hormones in cats are sparse, and little research has 
focused on adiponectin [72, 212].  
The basic component of adiponectin is a 30kDa molecule that combines with like 
molecules to form 90 kDa trimers. These trimers are referred to as low molecular weight (LMW) 
forms of adiponectin [130]. The LMW forms of adiponectin can also combine to make middle 
molecular weight (MMW) and high molecular weight (HMW) forms of the hormone. The HMW 
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form is made up of twelve or more adiponectin molecules bound together and is likely the most 
active form of the hormone. Recent studies show the HMW form is more closely associated with 
insulin resistance and diabetes than total adiponectin or the lower weight forms [132, 133]. The 
HMW and LMW forms of adiponectin have not been previously described in the cat. The 
translated amino acid sequence of feline adiponectin is similar to canine (91%), mouse (88%), 
and human (85%) adiponectin (Genbank numbers FJ621262, NP_001006645, AAZ86518, 
NP_004788). Therefore, it is likely that cats form the same adiponectin structures found in other 
species.  
As researchers begin to study feline adiponectin, it is important to understand how gender 
influences concentrations of this hormone. Women have higher amounts of both total and HMW 
adiponectin than men [161, 162]. Evidence that male hormones lower adiponectin levels is found 
in studies of immature boys and castrated mice. As pre-pubescent boys mature, their adiponectin 
levels decrease [163]. Neonatal castration of male mice results in adiponectin concentrations 
similar to female mice, and ovariohysterectomy of female mice raises adiponectin concentrations 
[164]. Based on data in human beings and rodents, one would expect spayed female cats to have 
high levels of adiponectin and intact male cats to have relatively low concentrations. 
Gender and neuter status influence the development of obesity and diabetes in cats. 
Spayed and neutered cats are more likely to gain excess fat, and male cats have a greater risk for 
diabetes than female cats [291, 301, 347].  Because adiponectin is a potent insulin sensitizer, it 
may directly contribute to the gender bias found in the distribution of obesity and diabetes 
mellitus among domestic felids. Therefore, this study compared total adiponectin and HMW to 
LMW ratios in neutered male, spayed female, intact male, and intact female cats.  
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Materials and Methods 
Animals 
Four groups of cats were evaluated: spayed females (SF)(n=12), intact females 
(IF)(n=14), neutered males (NM)(n=12), and intact males (IF)(n=14). Sexually altered animals 
were healthy, client-owned cats between the ages of 1-6 years. Intact cats were sampled during a 
community-based feral cat spay and neuter program. Blood samples from intact cats were 
collected after sedation and before surgery. Sedation was performed with a mixture of ketamine,1 
telazol,2 and xylazine3 injected intramuscularly. To test the effect of sedation on adiponectin 
concentrations, 2 female and 4 male cats undergoing routine spays and castrations were tested 
before and after sedation. The drugs did not significantly impact adiponectin concentrations 
(paired t-test, p>0.1). Feral cats were estimated to be between 1-6 years of age. All cats were 
lean with body condition scores (BCS) between 4-6 on a 9 point scale. Body condition score 
evaluations were performed by the same investigator. All cats were fasted for at least 12 hours 
prior to blood collection. Complete blood counts, chemistry and electrolyte panels were 
evaluated in all cats. Urinalyses were performed on client-owned cats. All cats appeared healthy 
on physical examination and via laboratory testing. All experimental protocols were approved by 
the University of Tennessee’s Institutional Animal Care and Use Committee. Pet owners 
provided informed consent before entering the study.  
                                                 
1
 Ketamine, Vedco, St. Joseph, MO 
2
 Telazol, Fort Dodge, Madison, NJ 
3
 Xylazine, Vedco, St. Joseph, MO 
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Measuring Adiponectin 
Total serum adiponectin concentrations were measured using a commercial murine 
sandwich ELISA kit validated for use in cats (see Chapter IV).1 Serum samples were stored at -
80°C until being diluted (1:1,000) and run in duplicate according to the manufacturer’s protocol. 
To measure multimeric forms of adiponectin, size exclusion gel chromatography was used to 
separated feline serum into fractions of protein <200 kDa or > 200kDa.2 The column was packed 
with composite polyacrylamide-agarose beads with a fractionation range of 20-350 kDa.3 The 
suspension was rinsed and soaked in PBS buffer before packing the column. 250µl of serum 
from each sample was treated with 1µl of the protease inhibitor, aprotinin,4 and loaded onto the 
column. The flow rate was 0.8 mls/min and 1.5 ml fractions were collected.5 The first 50 mls of 
column flow, which did not contain protein, was discarded for each sample. The presence of 
protein was detected in the collected fractions using bicinchoninic acid (BCA) protein analysis.6  
To determine which protein fractions were >200 kda (HMW) and <200kda (LMW), 
samples were run on a non-reducing 4-15% gradient SDS-PAGE gel.7 The gel was then stained 
with Coomassie blue stain.8 The first fifteen protein samples collected from the column 
consistently contained the large protein fractions. Once serum proteins were separated into 
>200kda and <200kda size, the amount of adiponectin present in each group was tested in 
duplicate using the ELISA method above. Samples were diluted 1:10. SDS-PAGE gels were 
repeated for every 10 samples tested or anytime the column was repacked with beads. Protein 
                                                 
1
 Murine adiponectin ELISA kit, B-Bridge International, Sunnyview, CA 
2
 BioLogic LP, Bio Rad, Hercules, CA 
3
 Ultrogel AcA 34, Sigma-Aldrich, St. Louis, MO.  
4
 Aprotinin, Fisher Bioreagents, Pittsburgh, PA 
5
 Fraction collector model 2110, Bio Rad, Hercules, CA 
6
 BCA protein assay, ThermoFisher Scientific, Pittsburgh, PA 
7
 Ready Gel Tris-HCl Gel, 4–15% linear gradient, Bio Rad, Hercules, CA  
8
 Gel Code Blue stain, ThermoFisher Scientific, Pittsburgh, PA 
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assays were performed for every sample tested. The ratio of HMW adiponectin was determined 
using the formula: HMW/(HMW+LMW) where LMW represents all forms of adiponectin 
<200kDa. This ratio has been used extensively in adiponectin research, and is a more accurate 
predictor of insulin sensitivity than total adiponectin [132, 133].  
Statistical Analysis 
The number of cats needed for the project was determined using: alpha = .05, power = 
80%, standard deviation = 0.1, r = .80, and significant unit difference of adiponectin = 0.0375 µ 
g/ml.  Descriptive statistics (means, standard deviations, and coefficients of variation) were 
analyzed using SPSS v. 9.1.1  Group body weights and adiponectin levels were compared using 
one-way analysis of variance (p<0.05). If statistical significance was found, then a Bonferoni-
Dunn post-hoc test was performed. Normality of data was confirmed using Shapiro-Wilk testing. 
For BCS, a Kruskal-Wallis test (nonparametric equivalent of ANOVA) was done. 
Results 
Body weights differed significantly among all groups except for IM and SF (p<0.05) 
(Table 5A). There was no difference in BCS between groups. Mean (+/- SD) total adiponectin 
and HMW ratio values for each group are presented in Figures 5A-D. Raw data for total 
adiponectin, HMW ratios of adiponectin, body weight, and BCS can be found in Appendix A. 
Total adiponectin did not differ between groups. However, when total adiponectin was adjusted 
for body weight (adiponectin/BWkg), NM had significantly less adiponectin than SF and IF 
(p<0.005). The HMW ratio was significantly higher in intact females compared to spayed 
females (p<0.05). When the HMW ratio was adjusted for body weight (% HMW  
                                                 
1
 SPSS v. 9.1, SPSS Inc., Chicago, IL 
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Group Mean Body Weight (kg) 
Spayed Females 3.87 (+/-0.66) 
Intact Females 3.12 (+/- 0.45) 
Neutered Males 5.07 (+/- 0.76) 
Intact Males 4.06 (+/- 0.78) 
Mean body weights (kg) of cats +/- two standard deviations. Body 
weights differed significantly between all groups except for spayed 
females and intact males (p<0.05). Body condition scores did not 
differ among groups. 
Table 5A. Mean Body Weights  
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Figure 5A: Mean Total Adiponectin 
Figure 5A: Mean total adiponectin for each group (+/- SD). There was no statistical 
difference between the groups: intact females (IF), spayed females (SF), intact 
males (IM), and neutered males (NM) 
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Figure 5B: Mean Total Adiponectin Corrected for Body Weight 
Figure 5B: Mean total adiponectin divided by body weight in kilograms (+/- SD). 
Neutered males (NM) had significantly less adiponectin than spayed females (SF) 
and intact females (IF) (p<0.005). There was no statistical difference between intact 
males (IM) and (NM). Values with different superscript letters differ significantly. 
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Figure 5C: Mean HMWR of Adiponectin 
Figure 5C: Mean HMWR of adiponectin (+/- SD). Intact females (IF) had 
significantly higher percentages of HMW adiponectin than spayed females 
(SF)(p<0.05). There was no statistical difference between intact (IM) and neutered 
males (NM) and the females. Values with different superscript letters differ 
significantly. 
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Figure 5D: Mean HMWR of adiponectin divided by body weight in kilograms (+/- 
SD). Neutered males (NM) had significantly lower percentages of HMW adiponectin 
than all other groups (p<0.05) (IF) had significantly higher percentages of HMW 
adiponectin than all other groups (p<.05). IM=intact male, SF=spayed female. Values 
with different superscript letters differ significantly. 
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Figure 5D: Mean HMWR of Adiponectin Corrected for Body Weight 
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adiponectin/BWkg), NM had a significantly lower percentage of HMW adiponectin than SF 
(p<0.01), IF (p<0.001), and IM (p<0.05). IF also had higher percentages of HMW adiponectin 
than IM (p<0.05) and SF (p<0.001).  All cats had higher concentrations of HMW than LMW 
adiponectin with the HMW forms representing about 80% of total adiponectin in cats. The mean 
total adiponectin concentration for all cats in the study was 0.93 µg/ml (+/- 1.2). 
Discussion 
This is this first study to measure multimeric forms of adiponectin in cats. High 
molecular weight forms of adiponectin are more closely associated with insulin sensitivity in 
people and are the active form of this hormone [348]. Therefore, the ability to measure HMW 
adiponectin in cats is important for determining adiponectin’s role in feline metabolism. Women 
have higher concentrations of total adiponectin and HMW adiponectin than men. In a recent 
study of 187 lean and obese individuals, HMW adiponectin made up 35% of total adiponectin in 
women and only about 16% in men [348]. These results are very different from our findings 
where HMW adiponectin constitutes almost 80% of total adiponectin in cats. Cats also have 
lower circulating concentrations of total adiponectin than humans. Our study showed a range of 
0.25 to 2.97 µg/ml in lean cats, while lean humans have concentrations about tenfold higher. 
However, the total adiponectin range for cats is similar to dogs [349]. 
Total adiponectin concentrations in this study did not differ by gender until a correction 
for body weight was made. Following the correction, neutered male cats had significantly less 
adiponectin than both groups of female cats. Male cats tend to have larger body frames and 
weigh more than female cats. By dividing total adiponectin concentrations by the body weight, 
we may have artificially lowered the adiponectin concentrations in neutered males. Body weight 
corrections were used to try and adjust for possible differences in body fat mass between groups. 
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Accurate measurement of body fat mass requires DEXA and was beyond the scope of this study. 
Neutered males have the highest risk for developing T2DM [291], and low concentrations of 
total adiponectin may influence diabetes development and progression.   
The impact of sedation on adiponectin concentrations was tested in a separate group of 
cats and did not affect our results. Although cats in this study were considered feral, they reside 
in colonies where caretakers provide access to commercial cat food. Diet was not controlled for 
in this study because the macronutrient composition of diet has little or no influence on 
adiponectin concentrations [72, 350]. Adiponectin concentrations can be lowered by stress, and 
the feral cats in this study probably lead more physically and emotionally stressful lives than pet 
cats [351]. This study found neutered males to have the lowest concentrations of adiponectin, 
and they would presumably be less stressed than the intact cats. However, based on the 
disposition of pet cats tested, traveling to the veterinary hospital and being restrained for blood 
collection also induced a substantial degree of stress in the pet cat population.  
Intact females had higher percentages of HMW adiponectin compared to spayed females. 
This finding suggests ovarian hormones influence adiponectin multimerization. A recent in vitro 
study using human fat cells showed incubation of adipocytes with male and female serum down 
regulated adiponectin expression, with male serum being more inhibitory. However, subjecting 
cells to testosterone and estradiol did not influence expression or adiponectin multimers [165]. 
Perhaps there are undetermined serum factors that cause females to produce more adiponectin. 
Following correction for body weight, NM had a lower percentage of HMW adiponectin and IF 
had a higher percentage of HMW adiponectin than all other groups. As with total adiponectin, 
correcting body weight may have artificially lowered the HMWR in male compared to female 
cats. Low concentrations of HMWR adiponectin are more closely associated insulin resistance 
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than total adiponectin.  Low HMWR of adiponectin in neutered males may therefore contribute 
to their increased risk of T2DM. More research is needed evaluating overweight cats to 
determine if adiponectin concentrations fall dramatically in male cats as they gain body fat. In 
addition, male cats may have decreased adiponectin receptor numbers or function that could 
impact biological efficacy.  
In summary, approximately 80% of feline adiponectin circulates in the HMW form, and 
intact female cats have a higher percentage of HMW adiponectin compared to spayed females. 
After correcting for body weight, NM cats had lower concentrations of total adiponectin than 
females and lower percentages of HMW adiponectin than all other groups. In addition to 
establishing the influence of gender on circulating adiponectin concentrations, this study 
provides normal ranges of adiponectin and HMW ratios for lean, young-adult cats. Using the 
information provided from this study, future research can evaluate the impact of age and obesity 
on adiponectin and study adiponectin as a predictor for the development of diabetes mellitus in 
domestic cats. 
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CHAPTER VI 
RELATIONSHIP OF ADIPONECTIN AND ITS MULTIMERS TO 
METABOLIC INDICES IN CATS DURING WEIGHT CHANGE 
 
Introduction 
According to the 2003-2004 National Health and Nutrition Examination Survey 
(NHANES), approximately 66% of adults in the United States are overweight or obese [233]. 
This epidemic of human obesity is reflected in our pet population. The prevalence of overweight 
and obese cats in the United States has risen almost 30% over the past 25 to 30 years [292, 293].  
This dramatic rise in feline obesity has also increased the prevalence of feline diabetes mellitus 
from 8 cases per 10,000 cats in 1970 to 124 cases per 10,000 cats in 1999 [291]. This trend is 
expected to continue, and researchers and veterinarians need to investigate new ways of 
combating obesity and diabetes in cats. 
 Discoveries within the past twenty years revealed that adipose tissue is an active 
endocrine organ secreting over 100 different proteins and cytokines called adipokines [1]. Two 
of the best studied adipokines are leptin and adiponectin. Leptin’s main action is to regulate body 
fat mass. As fat concentrations rise, leptin is released from adipocytes and targets the 
hypothalamus to reduce food intake and increase energy expenditure [32]. Leptin correlates 
positively with body fat mass in cats [68-72], and appears to correlate positively with insulin 
resistance, independent of adiposity [73]. 
Adiponectin is an anti-inflammatory hormone secreted almost exclusively from 
adipocytes. Although adiponectin is produced by adipose tissue, its plasma concentrations 
decline as body fat mass rises. Adiponectin is closely associated with insulin sensitivity in man, 
independent of body fat mass, and is an early marker for individuals at risk for T2DM [183-185, 
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346]. The basic component of adiponectin is a 30kDa molecule that combines with like 
molecules to form 90 kDa trimers. These trimers are referred to as low molecular weight (LMW) 
forms of adiponectin [130]. The LMW forms of adiponectin can further combine via disulfide 
linkages to create middle molecular weight (MMW) and non covalent aggregates of high 
molecular weight (HMW) forms. The HMW form is made up of twelve or more adiponectin 
molecules, and recent studies show the HMW form is more closely associated with insulin 
resistance and diabetes in man than total adiponectin or LMW forms [132, 133]. Research 
focusing on feline adiponectin is very limited. Total adiponectin was shown to correlate 
inversely with body mass as cats gain and lose weight [72], but no studies have evaluated the 
HMW form. In addition, the relationships between adiponectin, insulin sensitivity, and leptin 
have not been described.  
Obesity in man is characterized by a decrease in high density lipoprotein (HDL) 
cholesterol and an increase in triglyceride-containing lipoproteins [352]. Obese cats have higher 
concentrations of very low density lipoproteins (VLDL) than lean cats, but have similar 
concentrations of LDL. Unlike humans, acutely obese cats have higher concentrations of HDL 
cholesterol than lean cats [290]. Cats lack cholesterol ester transfer protein (CETP), a protein that 
aids in the transfer of cholesterol esters from HDL to lower density apo-B containing 
lipoproteins [274]. It is the absence of CETP in cats which is likely responsible for the high 
circulating HDL concentrations found in obese felids [234, 290]. High adiponectin 
concentrations are associated with higher concentrations of HDL cholesterol in man, but its 
relationship with lipoproteins in cats has not been evaluated [196, 198, 352]. 
Researchers have devoted immense resources toward the study of leptin and adiponectin 
in human beings and rodents, yet only a handful of studies have evaluated these hormones in our 
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most popular pet species [353]. The goal of this study was to therefore determine the relationship 
between total and HMW adiponectin and body fat mass, insulin sensitivity, leptin, and 
cholesterol lipoproteins in cats that gain and lose weight. In addition, we examined changes in 
adiponectin mRNA expression in the subcutaneous adipose tissue and compared the expression 
patterns to circulating adiponectin concentrations. 
Materials and Methods 
Animals 
 Twenty adult (1-11 years) laboratory cats belonging to the University of Tennessee 
College of Veterinary Medicine were classified into one of two weight categories, overweight or 
lean, based on body fat percentage. The overweight cats were placed into a weight loss group (L) 
while the lean cats were placed in a weight gain group (G). All cats appeared healthy based on 
physical examination and routine laboratory testing. Overweight cats had body condition scores 
between 6-9 and lean cats had scores between 3-5 on a nine point scale. Both groups consisted of 
one intact female, 4 spayed females, and 5 neutered males. All cats in the L group were fed a 
nutritionally balanced commercial dry cat food.1 Each cat was initially fed 80% of their resting 
energy requirements at ideal body weight to achieve a weight loss rate of 1-2% of body weight 
per week. If the rate of weight loss slowed to less than 1% per week, food intake was adjusted. 
Cats in the G group were fed ad lib one of three different commercial diets, depending on taste 
preferences.1,2,3 All protocols were approved by the University of Tennessee’s Institutional 
Animal Care and Use Committee. 
                                                 
1
 Dietetic Management (DM), Nestlé Purina Petcare Company, St. Louis, MO 
2
 c/d feline dry, Hills Pet Nutrition, Inc., Topeka, KS 
3
 Whiskas feline dry, Mars Incorporated, Hackettstown, NJ 
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Experimental Protocol 
Frequently sampled intravenous glucose tolerance testing (FSIVGTT), fat biopsies, 
HMW adiponectin, total adiponectin, leptin, cholesterol profiles, and body fat measurements 
were performed at the beginning and end of the study for each cat (Figure 6A). In addition, total 
adiponectin, leptin, simplified measures of insulin sensitivity, and body fat were measured as 
cats gained or lost at least 5% of their body weight. The study ended for cats in the L group when 
they lost at least 10% of their body fat mass or reached an ideal body condition score (4 or 5/9). 
Cats in the G group left the study after they gained at least 10% body fat mass or their weight 
gain plateaued.  
Insulin sensitivity testing 
Assessment of insulin sensitivity at the start and end of the study was performed using 
the insulin-modified frequently sampled modified intravenous glucose tolerance (FSIVGTT) 
with minimal model analysis [325, 354]. A central venous catheter (jugular or medial saphenous) 
was placed under general anesthesia the day before testing. Premedication with butorphanol 
intramuscularly (0.2mg/kg) was followed by anesthetic induction and maintence with 
sevoflurane. After recovering from anesthesia, cats were returned to their normal living 
enviroment to minimize stress. Following a 16-18 hour fast, the FSIVGTT was performed the 
next day. Thirty-one blood samples were collected to measure insulin and glucose over three 
hours. Four baseline blood samples were collected at times –15, –10, –5, and –1 minutes. At time 
0, a bolus of 50% dextrose (0.5 g/kg)1 was injected intravenously. Blood samples were collected  
 
                                                 
1
 50% Dextrose, Hospira, Lake Forest, IL 
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Figure 6A: Study Outline 
Figure 6A: Outline of the study protocol and the types of data collected at intervals during 
the study. Depending on the degree of weight change, some cats had up to 6 interval 
testing days. 
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over the next 3 hours at 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 19, 22, 24, 25, 27, 30, 40, 50, 60, 70, 80, 
90, 100, 120, 140, 160, and 180 minutes.Twenty minutes after glucose injection, regular human 
insulin1 (0.05 U/kg) was injected via the central catheter. Just prior to the FSIVGTT, blood was 
also collected to measure adiponectin, leptin, and cholesterol. The FSIVGTT with minimal 
model analysis indirectly measures insulin sensitivity. During the first 7-10 minutes after the 
dextrose bolus (t = 0) the pancreas is stimulated to secrete insulin, and gluconeogenesis in the 
liver slows. After this initial phase, glucose disposal is mediated almost completely by glucose 
for the next ten minutes (t = 20min). This glucose-mediated glucose disposal is referred to as 
glucose effectiveness (SG). Once insulin is injected (t = 20 min) glucose disposal becomes 
insulin-mediated. The amount of glucose removed from circulation in relation to the amount of 
insulin injected is the insulin sensitivity value (SI). One’s ability to secrete endogenous insulin 
can also be estimated by measuring the levels of insulin secreted after the glucose bolus and 
before the insulin injection. This is referred to as the acute insulin response to glucose (AIRG). 
The adequacy of insulin secretion and insulin action to dispose of glucose is called the 
disposition index (DI) and is calculated by multiplying the SI by the AIRG [324]. 
Less invasive methods for insulin sensitivity testing were measured by determining the 
fasting glucose, fasting insulin, fasting glucose to insulin ratio, and by performing a homeostasis 
model assessment (HOMA). All of these methods relied on a single fasting blood sample to 
measure glucose and insulin concentrations. 
                                                 
1
 Humulin R, Lilly, Indianapolis, IN 
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Body Fat Mass 
Body fat mass was measured using dual energy X-ray absorptiometry (DXA).1 DXA 
scans were performed at the beginning and end of the study and when cats gained or lost 
approximately 5% of their body weight. Cats were placed under general anesthesia using 
sevoflurane2 after receiving a premedication of butorphanol3 intramuscularly (0.2mg/kg).  
Adiponectin and HMW adiponectin 
Total serum adiponectin concentrations were measured using a commercial murine 
sandwich ELISA kit validated for use in cats (see Chapter IV).4 Serum samples were stored at -
80°C until being diluted (1:1,000) and run in duplicate according to the manufacturer’s protocol. 
Using the same protocol described in Chapters IV and V, the multimeric forms of adiponectin 
were measured using size exclusion gel chromatography followed by an adiponectin-specific 
ELISA. The ratio of HMW adiponectin was calculated using the equation: 
HMW/(HMW+LMW) where LMW represents all forms of adiponectin <200kDa. 
Leptin 
Leptin concentrations were measured using a multispecies radioimmunoassay validated 
for use in cats [68].5 Validation in our laboratory showed an intra and interassay variation of 
6.5% and 9.5%. According to the manufacturer, the lower limit of assay detectability is 1ng/ml. 
                                                 
1
 Lunar DPX, GE Healthcare, Waukesha, WI 
2
 Sevoflurane, Abbott, Abbott Park, IL 
3
 Butorphanol, Fort Dodge, Madison, NJ 
4
 Murine adiponectin ELISA kit, B-Bridge International, Sunnyview, CA 
5
 Multispecies Leptin, Millipore, Billerica, MA   
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Insulin 
Insulin concentrations were measured using commercial porcine insulin 
radioimmunoassay kit.1 This kit has been used extensively by other researchers in the field of 
feline diabetes [355]. Within our laboratory, the intra and interassay variation was 7.3% and 
7.2%. According to the manufacturer, the lower limit of assay detectability is 2 µU/ml. 
Glucose 
Glucose concentrations were measured during the FSIVGTT using a portable 
glucometer.2 This machine requires only one drop of blood and thereby reduced the blood 
volume collected. Glucose samples collected in between FSIVGTT were quantified using a non-
discrete chemistry analyzer.3 
Cholesterol 
Total cholesterol levels were measured using a discrete chemistry analyzer.4 HDL, LDL, 
and VLDL cholesterol fractions were measured using a lipoprotein electrophoresis kit following 
the manufacture’s protocol.5 Band intensities were quantified using a visible scanning 
densitometer.6 
Adiponectin mRNA expression 
Subcutaneous fat biopsies were collected from the inguinal fat pad at the beginning and 
end of the study. Cats were under general anesthesia for the DXA scan and central line catheter 
                                                 
1
 Porcine Insulin, Millipore , Billerica, MA   
2
 Accu-check Active meter, Roche Diagnostics, Indianapolis, IN 
3
 Cobas Mira, Roche Diagnostics, Indianapolis, IN 
4
 Hitachi 911, Roche Diagnostics, Indianapolis, IN 
5
 Lipoprotein electrophoresis, Beckman Coulter, Fullerton, CA 
6
 Quick Scan 2000 v.2, Helena Laboratories, Beaumont, TX 
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placement. Biopsy sites were injected with the local anesthetic septicaine to provide pain relief. 
Fat specimens were stored in RNA stabilizer1 and immediately frozen to -80°C.  Messenger 
RNA was extracted using a lipid-specific extraction kit.2 On-column DNase digestions were 
performed during the extraction3 and samples were stored at -80°C. Reverse-transcription (RT) 
was performed on each sample according to the SuperScriptTM II Reverse Transcriptase 
manufacturer protocol.4 The reverse priming and quantitative, real-time (Q) PCR were 
performed with the following primers and FAM labeled probe designed for this study.5 They 
included forward primer (18 µM): 184 – CCGGGTGAAAAGGGTGAG – 201, probe (5µM): 
222 – AACAAGACCTGGATCTCCT – 204, and reverse primer (18 µM): 245 – 
TCACCAGTGTCACCCTTAGGA – 225. cDNA sequence locations correspond to GenBank 
accession number AB115956. The specificity of the primers and probe were confirmed through 
DNA sequencing of the PCR product [212]. For Q-PCR, cDNA (2µl) was combined with the 
primer and probe mixture (1µl),6 Taq polymerase (2x concentration, 10µl),7 and water (7µl). The 
total reaction volume was 20 µl. The amplification profile consisted of 2 min at 50ºC and 10 min 
at 95ºC, followed by 40 cycles of 95ºC for 15 sec and 60ºC for 1 min.  
To confirm linearity of each Q-PCR assay performed, a standard curve of adiponectin 
DNA using ten fold dilutions ranging from 1x101 to 1x105 was measured. To obtain a consistent 
                                                 
1
 RNAlater, Qiagen, Valencia, CA 
2
 RNeasy lipid tissue mini kit, Qiagen, Valencia, CA 
3
 RNase-free DNase set, Qiagen, Valencia, CA 
4
 Superscript II Reverse Transcriptase, Invitrogen, Carlsbad, CA 
5
 Taqman custom gene expression assay, Applied Biosystems, Foster City, CA 
6
 Taqman custom gene expression assay, Applied Biosystems, Foster City, CA 
7
 Taqman Universal PCR master mix, Applied Biosystems, Foster City, CA 
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number of adiponectin DNA copies, a plasmid with an adiponectin gene insert was constructed.1 
Standard curve equations were developed using SPSS v. 15.2   
Statistical Methods 
The number of cats needed for the project was determined using: alpha = .05, power = 
80%, standard deviation = 0.1, r = .80, and significant unit difference of adiponectin = 0.0375 
µg/ml.  Descriptive statistics, correlations, and paired t-tests were performed using SigmaStat.3  
Normality was assessed using the Shapiro-Wilk method. Non-parametric data was evaluated 
using the Wilcoxon signed rank test.  Stress hyperglycemia is a common occurrence in cats and 
can alter data regarding insulin sensitivity. Therefore, data from sampling days where cats had 
fasting blood glucose levels two standard deviations above the mean were omitted from analysis. 
Results 
The mean starting body weight for L cats was 6.0 kg (+/- 0.96) and for G cats was 4.0 kg 
(+/- .63). The mean starting body fat percentage was 34.5 (+/- 7.5) and 14.8 (+/- 7.0) for L and G 
cats, respectively. L cats lost an average of 1.61 kg (+/- 1.0) and 13.6% (+/- 3.9) body fat while 
G cats gained an average of 0.9kg (+/- 0.4) and 10.9% (+/- 4.0) body fat. The distribution of 
body weight and body fat percentages can be found in Figures 6B and 6C, respectively. The 
mean fasting glucose for all cats was 110 +/- 60 mg/dl. There were four instances during the 
study where a cat had fasting blood glucoses two standard deviations above the mean (>170 
mg/dl). Since these data points were  
 
                                                 
1
 TA cloning kit (pCR 2.1), Invitrogen, Carlsbad, CA 
2
 SPSS v. 15, SPSS Inc., Chicago, IL 
3
 SigmaStat, SYSTAT Software Inc., Chicago, IL 
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Figure 6B: Box and whisker plot of body weight in the weight loss (L) 
cats and weight gain (G) cats at the start and end of the study. The 25th 
and 75th quartiles are displayed as q1 and q3, respectively.  
 
Figure 6C: Body Fat Percentage 
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Figure 6C: Box and whisker plot of percent body fat mass in the weight 
loss (L) cats and weight gain (G) cats at the start and end of the study. The 
25th and 75th quartiles are displayed as q1 and q3, respectively.  
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statistical outliers, the insulin sensitivity data from those sampling days was omitted from 
analysis. Mean values for FSIVGTT results are listed in Table 6A. 
Body fat mass correlated positively with fasting glucose (r = 0.27, p<0.05) and negatively 
with AIRG (r = -0.36, p<0.05). When the area under the curve (AUC) for glucose was measured 
for the first twenty minutes of the FSIVGTT (time from dextrose bolus to insulin injection), it 
increased significantly in the G group (p>0.05) and trended towards a decrease in the L group 
(p>0.08). The AIRG also increased significantly in the G cats (p<0.05). The AUC curve for the 
entire FSIVGTT for glucose increased in the G  
group and decreased in the L group, but statistical power was too low to detect significance.  
Serum leptin concentrations correlated positively with fat mass (r = 0.74, p<0.0001). In 
the FSIVGTT, leptin correlated inversely with SG (r = -0.536, p<0.05) and AIRG (r = -0.506, 
p<0.01). Leptin also correlated positively with the AUC for glucose during the first 20 minutes 
of the FSIVGTT (r =0.656, p>0.05), but did not correlate with other markers of insulin 
sensitivity. Leptin did not correlate with total or HMW adiponectin. Mean leptin concentrations 
decreased significantly in cats that lost weight (p<0.05) but did not change in the cats that gained 
weight (Figure 6D).  
Total adiponectin did not correlate with body fat mass, body weight, or insulin 
sensitivity. Cats in the weight loss group had a mean starting adiponectin concentration of 1.5 
µg/ml, while the lean cats in the weight gain group had mean concentrations of 1.8 µg/ml. In 
addition, the median adiponectin concentration of L cats increased from 0.9 to 1.64 µg/ml and 
decreased from 1.6 to 1.3 µg/ml in the G cats (Figure 6E). These differences were not 
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Group SI SG AIRG DI 
L start 0.72(+/- 0.22) 0.023 (+/- 0.005) 
100.1 (+/- 
17.01) 44.7 (+/-11.7) 
L end 0.62 (+/- 0.25) 0.023 (+/- (0.004) 67.6 (+/- 27.1) 46.1 (+/-24.8) 
G start 0.96 (+/- .60) 0.034 (+/- 0.007) 119.9 (+/-20.7) 88.1 (+/-31.7) 
G end 0.87 (+/- 0.19) 0.030 (+/- 0.007) 87.7(+/- 25.92) 141.5 (+/-104.2) 
Figure 6D: Box and whisker plot of leptin (HE) in the weight loss (L) cats 
and weight gain (G) cats at the start and end of the study. Leptin 
decreased significantly in cats that lost weight (p<0.05) but did not 
change in the cats that gained weight. The 25th and 75th quartiles are 
displayed as q1 and q3, respectively.  
 
Figure 6D: Leptin 
Table 6A: Mean Insulin Sensitivity Indices from the FSIVGTT  
Table 6A: Mean insulin sensitivity indices (+/- SE) from the FSIVGTT. 
Samples were collected and the start and end of the study for cats that lost 
weight (L) and gained (G) weight. 
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Figure 6E: Box and whisker plot of adiponectin (µg/ml) in the weight loss 
(L) cats and weight gain (G) cats at the start and end of the study. The 25th 
and 75th quartiles are displayed as q1 and q3, respectively.  
 
Figure 6E: Total Adiponectin 
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statistically significant. Total adiponectin inversely correlated with total cholesterol (r = -0.502, 
p<0.005), but did not correlate with individual lipoprotein fractions. HMW adiponectin 
positively correlated with HDL cholesterol (r = 0.337, p<0.05). Cholesterol and lipoprotein 
distributions did not change significantly with weight change. The percentage of HDL 
cholesterol trended toward decreasing significantly in the weight gain group (p<0.06)(Figures 
6F-I). A sample of the lipoprotein electrophoresis results is found in Figure 6J.  
The HMW form made up the majority of adiponectin complexes with the average 
percentage being 82% (Figure 6K). HMW adiponectin correlated negatively with body fat mass 
(r = -.372, p<0.05) and positively correlated with two markers of glucose metabolism: 
glucose:insulin ratio (r = 0.34, p<0.05) and SG (r =.38, p<0.05). The mRNA expression of 
adiponectin in the subcutaneous fat increased by 5% with weight loss (p<0.05) and did not 
change with weight gain. mRNA expression also did not correlate with total or HMW 
adiponectin. 
Discussion 
 Previous studies in cats indicate total adiponectin concentrations decrease with increased 
fat mass [72, 345]. However, our study found no correlation between body fat mass and total 
adiponectin or changes in total adiponectin as cats gained and lost weight. There are several 
factors that may have limited our ability to detect a correlation or significant difference. The 
standard deviation of adiponectin in this study was much larger than anticipated (1.2 µg/ml). To 
detect a difference of 0.5 µg/ml in the study groups before and after weight change (80% power, 
p<0.05), an additional 28 cats would need to be added to the study. Individual cats also appeared 
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Figure 6F: Total Cholesterol 
Figure 6F: Box and whisker plot of total cholesterol (mg/dl) in the 
weight loss (L) cats and weight gain (G) cats at the start and end of the 
study.The 25th and 75th quartiles are displayed as q1 and q3, 
respectively.  
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Figure 6G: HDL Cholesterol 
Figure 6G: Box and whisker plot of HDL (alpha) cholesterol (%) in the 
weight loss (L) cats and weight gain (G) cats at the start and end of the 
study. The 25th and 75th quartiles are displayed as q1 and q3, 
respectively.  
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Figure 6H: LDL Cholesterol 
Figure 6H: Box and whisker plot of LDL (beta) cholesterol (%) in the 
weight loss (L) cats and weight gain (G) cats at the start and end of the 
study.The 25th and 75th quartiles are displayed as q1 and q3, 
respectively.  
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Figure 6I: VLDL Cholesterol 
Figure 6I: Box and whisker plot of VLDL (pre-beta) cholesterol (%) in 
the weight loss (L) cats and weight gain (G) cats at the start and end of 
the study.The 25th and 75th quartiles are displayed as q1 and q3, 
respectively.  
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Figure 6J: Sample Lipoprotein Gel Electrophoresis  
HDL VLDL LDL 
Figure 6J: A sample lipoprotein gel electrophoresis. HDL (alpha band) makes up the 
majority of cholesterol lipoproteins in cats.  The inset in the upper left corner of the 
graph shows the original gel. 
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Figure 6K: High Molecular Weight Adiponectin 
Figure 6K: Box and whisker plot of HMW adiponectin in the 
weight loss (L) cats and weight gain (G) cats at the start and end 
of the study. HMW adiponectin correlated negatively with body 
fat mass (R= -.372, p<0.05). The 25th and 75th quartiles are 
displayed as q1 and q3, respectively.  
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to have their own set point for adiponectin concentrations that could then increase or decrease 
with weight change.  For example, an obese cat in the weight loss group consistently had 
adiponectin levels >4 µg/ml while a very lean cat in the weight gain group had low 
concentrations ranging from 0.8 to 1.1 µg/ml. Finally, the changes in body fat mass may not 
have been dramatic enough to elicit a statistically significant difference. At approximately 25%, 
the mean body fat mass in the cats that gained weight was still below the range that is considered 
overweight or obese.  
The high molecular weight form of adiponectin made up the majority of circulating 
complexes (54-93%) with most cats having ratios between 75-90%. This finding is similar to the 
results in Chapter V. As with total adiponectin, group differences in the ratio of HMW 
adiponectin were not detected. However, HMW adiponectin did correlated negatively with body 
fat mass (r = -.372, p<0.05).  
 HMW adiponectin is the active form of adiponectin and correlates better with markers of 
insulin sensitivity than fat mass in humans [356]. HMW adiponectin did not correlate with 
markers of insulin sensitivity in this study. Stress hyperglycemia likely altered the results of 
insulin sensitivity testing. Cats are easily stressed, and despite efforts to maintain a normal 
routine during the FSIVGTT, several of the laboratory cats had fasting blood glucoses 
>120mg/dl and probably had alterations in insulin sensitivity secondary to the release of stress 
hormones. Even on days when a single blood sample was collected, the cats were removed from 
their normal dwellings and taken to a different room. As the study progressed, some cats 
anticipated blood collection and were visibly stressed before collecting samples. Although the 
insulin sensitivity measurements in this study were confounded by stress, increased 
glucose:insulin ratio and  SG are indicative of improved glucose metabolism, and HMW 
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adiponectin correlated positively with both these tests.  The SG measures glucose-mediated 
glucose uptake in the FSIVGTT. Acute hyperglycemia is known to enhance glucose oxidation 
within cells and suppress hepatic gluconeogenesis [357]. This aspect of the FSIVGTT may be 
less impacted by the release of stress hormones. In addition, stress can lower adiponectin 
concentrations in man and may have impacted results in some cats [351].  
Total adiponectin correlated negatively with total cholesterol and HDL cholesterol and 
positively with VLDL and LDL cholesterol. In general, total cholesterol is expected to increase 
with obesity and adiponectin is expected to decrease [333]. Therefore, the relationship between 
adiponectin and total cholesterol in this study is comparable to other species. In human beings 
and cats that have been obese for a long period of time, HDL cholesterol tends to decrease with 
obesity [290]. However, newly obese cats tend to have higher concentrations of HDL cholesterol 
and this fits with the relationship between adiponectin and HDL cholesterol found in this study 
[358]. As the percentage of HDL cholesterol increased with weight gain, the relative amounts of 
VLDL and LDL cholesterol decreased. The positive correlation between adiponectin and the 
percentage of these beta lipoproteins was most likely related to changes in the percentage of 
HDL cholesterol and not a cause and effect relationship. It has been suggested in humans that 
adiponectin exerts a positive influence on HDL concentrations [359]. The disconnect between 
adiponectin and HDL cholesterol in this study does not support the idea that adiponectin directly 
increases HDL cholesterol concentrations. 
The mRNA expression of adiponectin from subcutaneous adipose in the inguinal fat pad 
increased 5% with weight loss, but did not change with weight gain. mRNA expression also did 
not correlate with total or HMW adiponectin. Adiponectin undergoes extensive post-translational 
modifications, and its release from cells is tightly regulated. This dissociation between gene 
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expression and circulating adiponectin has also been demonstrated in human beings after gastric 
bypass surgery [360]. In addition, cats express more adiponectin from visceral than subcutaneous 
adipose (see results from Chapter III)[212]. Therefore, the subcutaneous adipose expression 
measured in this study may not have impacted circulating adiponectin concentrations as much as 
visceral adipose.  
Leptin correlated closely with body fat mass and negatively correlated with SG  and 
AIRG. The results from this study are similar to previous findings regarding feline leptin [69, 73]. 
AIRG represents the acute response to insulin and it decreased as leptin increased. If higher 
concentrations of leptin are indicative of increased fat mass, then a damped initial insulin release 
after the glucose bolus may reflect a pre-diabetic state and decreased pancreatic function. Leptin 
did not correlate with total or HMW adiponectin. Since leptin is closely tied to body fat mass and 
adiponectin in cats does not correlate as closely with adiposity, it is not surprising that these two 
hormones did not correlate in this study. 
In conclusion, feline adiponectin has many similarities with other species. Although our 
study was unable to find a relationship between total adiponectin and body fat mass, study design 
and limitations affected the results and other studies support a negative associations between 
adiponectin and fat mass in cats [72, 345]. This project was the first to compare HMW 
adiponectin to fat mass, and a negative correlation was found. In accordance with human and 
rodent studies, feline HMW adiponectin was a better marker for glucose disposal than total 
adiponectin, and may impact the development of T2DM. Cats tend to have lower circulating 
concentrations of adiponectin than human beings, but have higher percentages of the active, 
HMW form. While this study provides valuable initial information regarding feline adiponectin, 
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the variation in adiponectin concentrations requires a much larger study population to truly 
assess its relationship with insulin sensitivity and diabetes.  
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PROJECT SUMMARY 
 
Cats are unique creatures with many metabolic and physiologic adaptations that differ 
from man, mouse, and dog. The results of this project have also discovered characteristics unique 
to the cat regarding the hormone adiponectin. Unlike humans, cats appear to have higher 
adiponectin mRNA expression from visceral compared to subcutaneous adipose tissue. We 
found visceral adipose samples express approximately 12% more adiponectin mRNA than 
subcutaneous samples. This is in agreement with another study in cats in which visceral adipose 
expressed 50% more adiponectin than subcutaneous adipose [212]. This is an intriguing finding 
because humans secrete 25-60% less adiponectin from visceral fat [157, 339, 341]. Cats have 
about ten-fold lower serum concentrations of adiponectin compared to humans and rodents, but 
have similar concentrations to dogs [349, 361]. Although total serum adiponectin is 
comparatively low in felids, cats have a higher percentage of the active, high molecular weight 
form than people (approximately 80% in cats and 15-35% in people)[348].  
Although this project found some distinct characteristics of adiponectin in the cat, there 
were also similarities with human adiponectin. The feline adiponectin cDNA and amino acid 
sequences were highly homologous to dogs (91%, 91%), people (87%, 85%), and mice (84%, 
88%). Like humans and rodents, biologically significant amounts of adiponectin mRNA were 
expressed only from adipose tissue in cats. Female humans tend to have higher concentrations of 
adiponectin than males [348]. When adiponectin was corrected for body weight, our study found 
neutered male cats had lower concentrations of total adiponectin than female cats and lower 
percentages of HMW adiponectin than all other gender groups. Even before body weight 
correction, intact female cats had a higher percentage of HMW adiponectin than spayed females. 
Corrections for body weight were made in an attempt to correct for potential differences in body 
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fat mass. Ideally body fat mass would have been measured in the study. Male cats tend to have 
larger body frames than female cats and correcting for body weight may have artificially lowered 
adiponectin levels in male compared to female cats. Feline HMW adiponectin was a better 
marker for glucose disposal than total adiponectin. This finding is in accordance with human 
studies indicating HMW adiponectin is a better marker for insulin sensitivity than total 
adiponectin [340]. 
In addition to characterizing key aspects of adiponectin biology in the cat, this project 
also explored new methods for measuring feline adiponectin. A commercial adiponectin ELISA 
assay was validated for measuring total serum adiponectin in cats. To measure the ratio of HMW 
to LMW adiponectin, we developed a protocol combining size-exclusion gel chromatography 
with the ELISA.  
 While each chapter of this project presented its own minor limitations, the major pitfalls 
occurred in Chapter VI. When this study was designed, adiponectin had been measured in only a 
handful of cats. Therefore, we did not anticipate the wide range of adiponectin concentrations 
found in this study, and the project had too few cats to detect significant associations between 
total adiponectin and body fat mass. However, a negative correlation between body fat mass and 
HMW adiponectin was found. Another limitation to this study was the influence of stress on the 
study results. Cats are notorious for developing stress hyperglycemia with restraint and this 
significantly impacted measurements of insulin sensitivity. In addition, the study comparing the 
influence of gender on adiponectin would have been stronger if body fat mass had been directly 
measured. The most accurate method for assessing body fat mass is DEXA, and it was not 
feasible to use this technique in the feral cat population. We utilized body condition scoring to 
estimate body fat mass, but this method is not as precise. 
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 The discoveries and techniques developed during this project will facilitate many future 
studies regarding adiponectin in cats. By knowing the cDNA and amino acid sequences and 
understanding adiponectin’s mRNA expression, genetic studies and new measurement 
techniques can be developed. Validation of methods for measuring total and HMWR adiponectin 
in cats provides tools for other investigators to research adiponectin. In addition, understanding 
the influence of gender on adiponectin will help design future clinical studies. Neutered male 
cats are at higher risk for developing T2DM than other genders[291], and low adiponectin 
concentrations may contribute to the development of insulin resistance and diabetes. 
There is still much to learn regarding adiponectin in cats. The development of feline 
adiponectin antibodies and synthesized proteins could provide more sensitive and specific 
techniques for quantifying adiponectin proteins in blood or other tissues. Concentrations of total 
and HMWR adiponectin need to be characterized in a large, diverse population of cats, including 
those with naturally-occurring T2DM. Overweight neutered male cats are at higher risk for 
developing diabetes than other cats, and it would be interesting to further evaluate adiponectin in 
this population. In human beings, adiponectin is a very early marker for insulin resistance and 
subsequent diabetes mellitus, and a large, prospective study would be useful to determine if the 
same is true for cats. The study of feline adiponectin would not only benefit our pet population, 
but may also provide new insights into human diabetes mellitus. Felids are excellent models of 
T2DM in people and may be useful for testing the effects of adiponectin on disease development 
and treatment. Given the epidemic of obesity occurring in our human and pet populations, 
investigation of insulin-sensitizing hormones like adiponectin is important and hopefully this 
project will lay the groundwork for many future discoveries [362]. 
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